Myocardial  Ischemia  and Transfusion 
[STUDY_ID_REMOVED]  
October  24, 2017  
 
 
 
 
Jeffrey  L Carson,  MD 
Study Chair  
Principal Investigator, Clinical Coordinating Center 
Rutgers Robert Wood Johnson Medical School  
Maria  Mori  Brooks,  PhD 
Principal  Investigator, Data  Coordinating  Center 
University of Pittsburgh  
 
 
 
 
 
 
 
 
 
Version  7.1 1 

TABLE  OF CONTENTS  
A INTRODUCTION  ................................ ................................ ................................ ................................ ..........................  8 
A1 STATEMENT  OF COMPLIANCE  ................................ ................................ ................................ ................................ ... 8 
A2 STUDY  ABSTRACT  ................................ ................................ ................................ ................................ ....................  9 
A3 PRIMARY  HYPOTHESIS  ................................ ................................ ................................ ................................ .............  9 
A4 PURPOSE  OF THE  STUDY  PROTOCOL  ................................ ................................ ................................ .......................  10 
A5 SCHEMATIC  OF STUDY  DESIGN  ................................ ................................ ................................ ..............................  11 
A6 KEY ROLES  ................................ ................................ ................................ ................................ ............................  12 
B BACKGROUND  ................................ ................................ ................................ ................................ ..........................  13 
B1 PRIOR  LITERATURE  AND  STUDIES  ................................ ................................ ................................ ..........................  13 
B2 RATIONALE  FOR  THIS  STUDY : EQUIPOISE  ................................ ................................ ................................ ...............  18 
C STUDY  OBJECTIVES  ................................ ................................ ................................ ................................ ................  18 
C1 PRIMARY  AIM ................................ ................................ ................................ ................................ ........................  18 
C2 SECONDARY  AIMS................................ ................................ ................................ ................................ ..................  19 
C3 TERTIARY  AIMS ................................ ................................ ................................ ................................ .....................  19 
C4 RATIONALE  FOR  THE  SELECTION  OF OUTCOME  MEASURES ................................ ................................ ....................  20 
D STUDY  DESIGN  ................................ ................................ ................................ ................................ ..........................  21 
D1 OVERVIEW  OR DESIGN  SUMMARY  ................................ ................................ ................................ .........................  21 
D2 SUBJECT  SELECTION  AND  WITHDRAWAL  ................................ ................................ ................................ ...............  22 
2.a Inclusion  Criteria  ................................ ................................ ................................ ................................ ..............  22 
2.b Exclusion  Criteria  ................................ ................................ ................................ ................................ .............  23 
2.c Ethical  Considerations  ................................ ................................ ................................ ................................ ...... 23 
2.d Randomization  Method  and Blinding  ................................ ................................ ................................ .................  23 
2.e Subject  Recruitment  Plans  and Consent  Process  ................................ ................................ ...............................  24 
2.f Risks  and Benefits  ................................ ................................ ................................ ................................ ...................  24 
2.g Early  Withdrawal  of Subjects  from  Transfusion  Strategy  and Trial  Procedures  ................................ ...............  25 
2.h When  and How  to Withdraw  Subjects  ................................ ................................ ................................ ................  25 
2.i Data  Collection  and Follow -up for Withdrawn  Subjects  ................................ ................................ ........................  25 
D3 TRIAL  TRANSFUSION  STRATEGIES  ................................ ................................ ................................ ...........................  26 
3.a Description  ................................ ................................ ................................ ................................ .........................  26 
3.b Transfusion  Strategies  ................................ ................................ ................................ ................................ ........  26 
3.c Rationale  for Transfusion  Thresholds  ................................ ................................ ................................ ................  26 
3.d Method  for Assigning  Subjects  to Treatment  Groups  ................................ ................................ .........................  27 
3.e Preparation  and Administration  of Red Blood  Cell Transfusions  ................................ ................................ ...... 27 
3.f Subject  Compliance  Monitoring  ................................ ................................ ................................ .............................  28 
3.g Prior  and Concomitant  Therapy  ................................ ................................ ................................ ........................  29 
3.h Blinding  of Study  Intervention  ................................ ................................ ................................ ............................  29 
E STUDY  PROCEDURES  ................................ ................................ ................................ ................................ ...............  29 
E1 SCREENING  FOR  ELIGIBILITY  ................................ ................................ ................................ ................................ ... 29 
E2 SCHEDULE  OF MEASUREMENTS  ................................ ................................ ................................ ...............................  29 
E3 IN-HOSPITAL  FOLLOW -UP ................................ ................................ ................................ ................................ ........  30 
E4 FOLLOW -UP AT 30 DAYS ................................ ................................ ................................ ................................ .........  30 
E5 FOLLOW -UP AT 6 MONTHS  ................................ ................................ ................................ ................................ ...... 31 
E6 SAFETY  AND  ADVERSE  EVENTS  ................................ ................................ ................................ ..............................  31 
6.a Safety  and Compliance  Monitoring  ................................ ................................ ................................ ....................  31 
6.b Medical  Monitoring  ................................ ................................ ................................ ................................ ...........  31 
i Investigator  Only................................ ................................ ................................ ................................ .................  31 
ii Independent  Expert  to Monitor  ................................ ................................ ................................ ...........................  32 
iii Independent  Data  and Safety  Monitoring  Board  ................................ ................................ ................................ . 32 
6.c Definitions  of Adverse  Events  ................................ ................................ ................................ ............................  33 
6.d Classification  of Events  ................................ ................................ ................................ ................................ ...... 34 
i Severity  ................................ ................................ ................................ ................................ ..............................  34 
ii Relationship  ................................ ................................ ................................ ................................ ........................  34 
iii Expectedness  ................................ ................................ ................................ ................................ .....................  35 
6.e Data  Collection  Procedures  for Adverse  Events  and Unanticipated  Problems  ................................ .................  35 
6.f Reporting  Procedures  ................................ ................................ ................................ ................................ .............  36 
6.g Adverse  Event  Reporting  Period  ................................ ................................ ................................ ........................  37 
6.h Post-study  Adverse  Event  ................................ ................................ ................................ ................................ ... 37 
E7 STUDY  OUTCOME  MEASUREMENTS  AND  ASCERTAINMENT  ................................ ................................ .....................  37 
7.a Definitions  of Outcomes  ................................ ................................ ................................ ................................ ..... 37 
i Myocardial  Reinfarction  ................................ ................................ ................................ ................................ ...... 37 
ii Death  and Cause  of Death  ................................ ................................ ................................ ................................ . 38 
iii Unscheduled  Coronary  Revascularization  (unstaged)  ................................ ................................ ........................  38 
iv Readmission  to Hospital,  overall  and for primary  cardiac  diagnosis  ................................ ................................ ... 38 
v Unstable  Angina  ................................ ................................ ................................ ................................ .................  38 
vi Congestive  Heart  Failure  ................................ ................................ ................................ ................................ .... 38 
vii TIA or Stroke  ................................ ................................ ................................ ................................ ......................  39 
viii Deep  Venous  Thrombosis  or Pulmonary  Embolism  ................................ ................................ ...........................  39 
ix Bleeding  ................................ ................................ ................................ ................................ .............................  39 
x Infections  ................................ ................................ ................................ ................................ ............................  39 
xi Length  of Stay and Intensive  Care  Unit Days  ................................ ................................ ................................ ..... 40 
xii Quality  of Life ................................ ................................ ................................ ................................ .....................  40 
7.b Ascertainment  ................................ ................................ ................................ ................................ ....................  40 
E8 BASELINE  AND  INTERVENTION  CLINICAL  CHARACTERISTICS  ................................ ................................ ..................  41 
F STATISTICAL  PLAN  ................................ ................................ ................................ ................................ ..................  41 
F1 SAMPLE  SIZE DETERMINATION  AND  POWER  ................................ ................................ ................................ ................  41 
F2 INTERIM  MONITORING  AND  EARLY  STOPPING  ................................ ................................ ................................ .............  42 
F3 ANALYSIS  PLAN ................................ ................................ ................................ ................................ ..........................  46 
F4 STATISTICAL  METHODS  ................................ ................................ ................................ ................................ ...............  46 
4.a Baseline  Characteristics  of the Enrolled  Patient  Sample  ................................ ................................ ...................  46 
4.b Adherence  to Assigned  Intervention  ................................ ................................ ................................ ...................  47 
4.c Primary  Outcome  Analysis  ................................ ................................ ................................ ................................  47 
4.d Analysis  of Secondary  and Tertiary  Outcomes  ................................ ................................ ................................ ... 47 
4.e Missing  Outcome  Data  ................................ ................................ ................................ ................................ ....... 48 
4.f Subgroup  Analyses  ................................ ................................ ................................ ................................ .................  49 
4.g Combining  Vanguard  and Main  Trial  Data  ................................ ................................ ................................ ....... 49 
F5 UNBLINDING  PROCEDURES  ................................ ................................ ................................ ................................ ..........  50 
G DATA  HANDLING  AND  RECORD  KEEPING  ................................ ................................ ................................ ........  50 
G1 CONFIDENTIALITY  AND  SECURITY  ................................ ................................ ................................ ..........................  50 
G2 TRAINING  ................................ ................................ ................................ ................................ ................................  51 
G3 CASE  REPORT  FORMS  AND  SOURCE  DOCUMENTS  ................................ ................................ ................................ ... 51 
G4 RECORDS  RETENTION  ................................ ................................ ................................ ................................ .............  52 
G5 PERFORMANCE  MONITORING  ................................ ................................ ................................ ................................ .. 52 
H STUDY  MONITORING,  AUDITING,  AND  INSPECTING  ................................ ................................ .....................  52 
H1 STUDY  MONITORING  PLAN ................................ ................................ ................................ ................................ ..... 52 
H2 AUDITING  AND  INSPECTING ................................ ................................ ................................ ................................ ..... 52 
I STUDY  ADMINISTRATION  ................................ ................................ ................................ ................................ ...... 53 
I1 ORGANIZATION  AND  PARTICIPATING  CENTERS  ................................ ................................ ................................ ...........  53 
1.a Clinical  Coordinating  Center  ................................ ................................ ................................ ............................  53 
1.b Data  Coordinating  Center  ................................ ................................ ................................ ................................ . 53 
1.c Clinical  Consortium  ................................ ................................ ................................ ................................ ...........  54 
I2 FUNDING  SOURCE  AND  CONFLICTS  OF INTEREST  ................................ ................................ ................................ .........  54 
I3 COMMITTEES  ................................ ................................ ................................ ................................ ...............................  54 
3.a Steering  Committee  ................................ ................................ ................................ ................................ ............  54 
3.b Operations  Committee  ................................ ................................ ................................ ................................ ....... 55 
3.c Executive  Committee  ................................ ................................ ................................ ................................ ..........  55 
3.d Clinical  Events  Committee  ................................ ................................ ................................ ................................ . 55 
I4 SUBJECT  STIPENDS  OR PAYMENTS  ................................ ................................ ................................ ...............................  55 
I5 STUDY  TIMETABLE  ................................ ................................ ................................ ................................ ......................  56 
J PUBLICATION  PLAN  ................................ ................................ ................................ ................................ .................  57 
K REFERENCES  ................................ ................................ ................................ ................................ .............................  58 
L APPENDICES  ................................ ................................ ................................ ................................ ..............................  66 
L1 APPENDIX 1: STANDARDIZED APPROACH AND SCRIPT TO BE USED TO SEEK PERMISSION FROM ATTENDING  
PHYSICIAN  TO RECRUIT  A PATIENT  ................................ ................................ ................................ ................................ ...... 67 
L2 APPENDIX  2: MINT  DATA  ELEMENTS  BY STUDY  TIME POINT ................................ ................................ ................  68 
L3 APPENDIX  3: SAE  AND  UP EVENT  REPORTING  TIMELINES  ................................ ................................ ....................  69 
L4 APPENDIX  4: ACCRUAL  TIMELINE  MILESTONES  ................................ ................................ ................................ .... 70 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 8  
  
 
A1 Statement  of Compliance  
 
The trial will be conducted in accordance with the ICH E6, the Code of Federal Regulations on the 
Protection of Human Subjects (45 CFR Part 46), and the NIH  Terms of Award. The Principal 
Investigator  will assure  that no  deviation  from,  or changes  to the protocol  will take place  without  prior 
agreement from the sponsor and documented approval from the Institutional Review Board (IRB), 
except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training.  
 
I agree  to ensure  that all  staff members  involved  in the conduct of  this study  are informed  about  their 
obligations in meeting the above commitments.  
Principal Investigator:   Jeffrey L Carson, MD   
Print/Type Name  
 
Signed:  Date:   
Signature  
AIntroduction  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 9  
  
A2 Study  Abstract  
Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in 
most clinical settings. However, a low oxygen carrying capacity from moderate anemia may be 
deleterious in patients with cardiac ischemia.  The potential for harm associated with anemia in 
patients with acute symptomatic coronary disease is supported by pathophysiological data that 
maintaining  higher  hemoglobin  levels  could  benefit  the ischemic  heart  by increasing  oxygen  delivery. 
Systematic reviews of clinical trials evaluating transfusion strategies in patients with known ischemic 
heart disease document the absence of high quality data, which has resulted in an ongoing 
controversy.  The lack of  high quality  evidence  to guide  transfusions  in patients  with acute  myocardial 
infarction has been cited in several major guidelines as well as by an NIH expert panel.  
This multicenter trial, the Myocardial Ischemia and Transfusion (MINT) trial, randomly allocates 3500 
patients with acute myocardial infarction and a hemoglobin concentration less than 10 g/dL to be 
treated either according to a liberal or restrictive blood transfusion strategy.  Patients assigned to the 
liberal transfusion strategy receive one unit of packed red blood cells following randomization and 
enough  blood  to raise  the hemoglobin  concentration to  10 g/dL or above  any time a concentration  less 
than 10 g/dL is detected. Patients assigned to the restrictive transfusion strategy are permitted to 
receive a transfusion if the hemoglobin concentration falls below 8 g/dL or if angina symptoms clearly 
related  to the anemia  occur  and are not controlled  with anti-anginal  medications.  Only enough  blood  is 
given to reach a hemoglobin concentration of 8 g/dL or relieve the symptoms. Transfusion is strongly 
recommended if the hemoglobin concentration falls below 7 g/dL.  
The transfusion  protocol  is followed  during  the index  hospitalization  (up to 30 days).  Each  patient is 
contacted at 30 days for a comprehensive follow -up for assessment of several relevant clinical 
outcomes.  Patients are  contacted  again at 180  days to ascertain vital status  for assessment of six - 
month mortality . 
A3 Primary  Hypothesis  
The primary  hypothesis is that among patients  with an acute  myocardial  infarction and  a hemoglobin 
concentration  less than 10 g/dL, a  liberal  transfusion  strategy  with a threshold  of 10  g/dL reduces  the 
rate of the  composite outcome of all -cause  mortality  or recurrent  nonfatal acute  myocardial  infarction 
through 30 days following randomization compared to a restrictive transfusion strategy with a 
threshold of 7 to 8 g/dL.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 10  
  
A4 Purpose  of the Study  Protocol  
The purpose of the trial is to assess red blood cell transfusion strategies that are currently used in 
clinical practice and important medical events.  Red blood cells are a limited and expensive medical 
therapy.  Physicians  frequently  transfuse  patients  to maintain  specific  (and often  differing)  hemoglobin 
levels, despite the lack of evidence supporting the strategy. The study results, which will determine 
the benefit (or risk) of a liberal transfusion strategy, will influence the allocation of red blood cells 
worldwide.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 11  
 
 
A5 Schematic  of Study  Design  
 
 
 
 
 
 
 
 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 12  
  
A6 Key Roles  
 
Principal  Investigator,  Clinical  Coordinating  Center  and Study  Chair 
Jeffrey L Carson, MD  
Provost, Rutgers Biomedical Health Sciences 
Rutgers  Robert  Wood  Johnson  Medical  School 
125 Paterson Street  
New Brunswick,  New Jersey  08901 
Telephone: 732 -235-7122  
FAX:  732-235-7144  
Email:jeffrey.carson@rutgers.edu  
Principal  Investigator,  Data  Coordinating  Center 
Maria Mori Brooks, PhD  
Professor  of Epidemiology 
University of Pittsburgh  
Graduate  School  of Public  Health  
A530  Crabtree  Hall / 130 DeSoto  Street 
Pittsburgh, PA  15261  
Telephone:  (412)  624-1618  
FAX:  (412)  383-5891  
Email:  mbrooks@pitt.edu  
 
Project  Scientist  
Simone  Glynn  MD, MSc,  MPH 
Branch Chief  
Blood  Epidemiology  and Clinical  Therapeutics  Branch 
Division of Blood Diseases and Resources  
National  Heart,  Lung,  and Blood  Institute 
Tel: 301 -435-0065  
Fax: 301-480-0867  
Email:  glynnsa@nhlbi.nih.gov  
 
Project  Officer  
Pablo  Cure,  MD, MPH 
Program Officer  
Blood  Epidemiology  and Clinical  Therapeutics  Branch 
Division of Blood Diseases and Resources  
National  Heart,  Lung,  and Blood  Institute,  NIH 
6701 Rockledge Drive, Room 9163  
Bethesda,  MD 20892 -7950  
Tel: +1-301-451-7431Email:  pablo.cure@nih.gov  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 13  
  
 
B1 Prior  Literature  and Studies  
Blood transfusion is a common medical intervention.  In the United States, more than 16 million red 
blood cell units are  transfused annually  to 3.4  million patients.(1)  Worldwide 108  million units of blood 
are collected per year.(2) Of all transfusions, approximately 25% of all red cells transfused are given 
to patients with a primary diagnosis of cardiac disease(3) and 8% of all cardiology admissions are 
transfused  with RBCs.(4)  The economic  ramifications  of this frequent  intervention  are significant.  The 
latest estimates of the cost of a red blood cell unit range from $522 to $1183 (mean, $761 +$294).(5) 
The safety of transfusion with respect to transmission of infectious agents has increased greatly 
throughout the past two decades, and complications are rare.(6, 7)  
Anemia and Cardiac Disease: Generating evidence to guide transfusion threshold decisions in 
patients with myocardial infarction is especially important because coronary artery disease is so 
common,(8) anemia is  present frequently  in this setting, and is  associated  with increased  mortality. A 
study of 44,242 patients with non -ST segment elevation myocardial infarction from 400 US hospitals 
found  22.2%  of patients  had a hematocrit  <30%  (Hgb  <10 g/dL).(9)  In-hospital  mortality  was 10.4%  in 
patients with Hgb <10 g/dL compared to 2.7% in patients with Hgb >10 g/dL.(10)  In a second study 
involving 17,676 patients with acute myocardial infarction, hospital -acquired anemia (Hgb <11 g/dL) 
developed in 20.1% of patients during the hospitalization. Patients with Hgb <9 g/dL had a strong 
association with mortality (odds ratio=3.39).(10) The mechanism of early mortality in patients with 
acute cardiac injury and anemia may be related to a low ischemic threshold leading to myocardial 
injury, congestive heart failure and ventricular arrhythmia.  
Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in 
most  clinical  settings(11 -14) with the possible  exception  of patients  with acute  coronary  syndrome.  
BBackground  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 14  
  
Most  reviews  and guidelines  define  a restrictive  transfusion  strategy  as the administration  of red cells 
once hemoglobin falls below either 7 or 8 g/dL while a liberal strategy is most often suggested as a 
transfusion trigger of 10 g/dL.  
Pathophysiology: The AABB (formerly called the American 
Association of Blood Banks) guidelines on Red Blood Cell 
Transfusion recently recommended the use of restrictive 
transfusion triggers in most patients with the exception of 
those with an acute coronary syndrome.(15, 16) Their 
rationale  – in the absence  of randomized  trial evidence  – was 16 
 
 
13 
 
 
10 
 
 
7 
 
 
4 
 
 
1 
6 7 8 9 10 11 12+ 
Preoperative  Hemoglobin  g/dL 
the large body of basic physiology and observational data would suggest that a restrictive strategy 
may be deleterious.  This is because oxygen delivery to the myocardium is flow dependent since the 
heart extracts a high percentage of oxygen.  Therefore, myocardial ischemia may be precipitated or 
worsened by low hemoglobin concentrations, especially in patients with coronary stenosis or active 
plaques.  Studies  performed  in canines  suggest  a decreased  ability  to tolerate  anemia  in the presence 
of coronary artery disease.(17 -19) Electrocardiographic changes consistent with ischemia are seen 
at hemoglobin concentration below 5 g/dL in normal animals but at 7 -10 g/dL with experimentally 
induced coronary artery disease.  
Data from patients who decline blood transfusion for religious reasons were congruent with animal 
data. In a retrospective cohort study that included 1,958 adult surgical patients who declined 
transfusion  for religious  reasons  and found  a significant  interaction  between  underlying  cardiovascular 
disease and preoperative Hgb level with respect to death (p=0.03).(20)  In patients with underlying 
cardiovascular disease the adjusted odds of postoperative death began to rise sharply at Hgb level  
<10 g/dL while in patients without underlying cardiovascular disease there was a more subtle rate of 
increasing  risk below  10 g/dL (see Figure  1). This study  does  not address  whether  transfusion  would 
improve outcome.  
Transfusion could be harmful by several possible pathophysiological mechanisms.  Transfusion has 
been shown to increase platelet reactivity and increase procoagulant proteins.(21) Stored red blood 
cells take time to replenish  2, 3 DPG levels  impairing  release  of oxygen(22, 23) and  have  low levels  of 
nitrous  oxide  impairing oxgen  delivery  and vasodilation.(24)  The membranes  of stored  red blood  cells 
may become deformed and plug microvascular vessels.(25, 26)  
 
 
 
 
 Odds Ratio  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 15  
  
Systematic Reviews, Observational Studies:  We have identified or conducted systematic reviews 
of both observational studies and clinical trials.  As expected, a systematic review of observational 
studies in all patients found that blood transfusion was associated with increased mortality and 
morbidity.(27) Two recent systematic reviews focusing specifically on patients with myocardial 
infarction  identified  10 studies  (9 observational  and 1 pilot trial) reporting  the effects  of transfusions  on 
mortality.(28, 29) Nearly all observational studies demonstrated an association between transfusion 
and higher mortality. The one exception was in a large study using Medicare billing data in 79,000 
patients with acute myocardial infarction.(30)  Transfusion was associated with a lower risk of death 
when patients had an admission hematocrit below 0.33 (equal to a hemoglobin concentration of 11 
g/dL)  (odds  ratio=  0.69;  95% CI, 0.53-0.89)  and relationship  between  transfusion  and better  outcomes 
increased as the hematocrit fell. Indeed, based on subgroup analyses, the authors of the systematic 
review report that the adverse effects of transfusion appear to be mitigated in patients with a 
hematocrit less than 0.33.  Unfortunately, observational studies cannot be used to evaluate the effect 
of red blood cell transfusion since the use of blood transfusion is a marker for illness burden.(29, 31) 
Thus, no matter how refined the adjustment is for differences in illness burden, it is difficult, if not 
impossible, to completely adjust for differences between patients receiving and not receiving blood 
transfusion.  
Systematic Reviews, Clinical Trials:  We have performed a systematic review of clinical trials 
evaluating transfusion triggers in a variety of populations that were published in the Cochrane 
database(32) and JAMA.(33) We have updated the review (34) and found that compared with higher 
hemoglobin transfusion thresholds (~10 g/dL), a hemoglobin transfusion threshold of 7 or 8 g/dL is 
associated with fewer red blood cell units transfused (mean difference, -1.22 units per patient), 
without adverse associations with mortality, cardiac morbidity, functional recovery, or length of 
hospital  stay.  The relative  risk for the association  of restrictive  versus  liberal  transfusion  on 30-day all- 
cause mortality was 0.99 (95% CI, 0.82 to 1.20).  
A recent meta -analysis of 11 selected trials enrolling patients with cardiovascular disease (including 
data obtained from authors from four trials) was recently reported. The risk ratio for the association 
between  transfusion  thresholds  and 30-day mortality  was 1.15 (95%  confidence  interval  0.88 to 1.50), 
but the  risk of acute  coronary  syndrome in patients in the  restrictive compared with liberal transfusion 
group was increased in nine trials (risk ratio 1.78, 95% confidence interval 1.18 to 2.70).(35).  This 
analysis is limited by  the fact that data are  only included  from 27% of the  eligible trials.  The results  of 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 16  
  
a meta -analysis in cardiac surgery patients reports trend favoring liberal transfusion (36) but the 
results  conflict  with another  analysis  in cardiac  surgery  patients  in which  no trend  was evident.  (34) 
Clinical  Trials  in Acute  Coronary  Syndrome : Our systematic  review  identified  two pilot clinical  trials 
that included patients suffering an  acute coronary  syndrome.  The first was a small pilot trial including 
45 patients with acute myocardial infarction.(37)  Patients with hematocrit less than 30% were 
randomly allocated to a liberal (hematocrit <30%) versus restrictive (hematocrit < 24%) transfusion 
threshold.  The primary clinical safety measurement of in -hospital death, recurrent myocardial 
infarction, or new  or worsening congestive heart failure occurred in 8 patients in the liberal arm and 3 
in the restrictive arm (p< 0.046). There were 2 deaths in restrictive group and 1 death in the liberal 
group.  The authors concluded a definitive trial was urgently needed.  
In contrast,  the MINT  pilot enrolled  110 patients  and found  the pre-defined  primary  outcome  of death, 
myocardial  infarction, or  unscheduled  revascularization  within  30 days  occurred  in 6 patients  (10.9%) 
in the liberal -transfusion strategy and 14 (25.5%) in the restrictive -transfusion strategy p=0.054).  
Death  at 30 days  was less frequent  with liberal  transfusion  1 (1.8%)  compared  to restrictive 
transfusion 7 (13.0%); p=0.032.  
Overall, there were 2 deaths in the liberal transfusion strategy and 9 deaths in the restrictive 
transfusion  strategy  (relative  risk=  3.74,  95% CI 0.80-17.49;  p=0.09)  when  the two trials  in acute 
coronary syndrome are combined.  
Other Trials (38) with Signal of Harm from Restrictive Transfusion : The two most recently 
published trials also found a higher mortality in patients in the restrictive transfusion group in patients 
with ischemic heart disease.  The Titre2 trial contrasted liberal transfusion (9 g/dL) and restrictive 
transfusion  (7.5 g/dL)  in postoperative  patients  undergoing  cardiac  surgery.  The short -term outcomes 
were comparable between the transfusion strategies, but at 90 days follow -up, overall mortality was 
higher in the restrictive transfusion strategy than the liberal transfusion strategy (hazard ratio=1.64; 
95% confidence interval, 1.00 to 2.67, p=0.045).  In a cluster randomized trial in 939 patients with GI 
bleeding, the mortality was trending higher in subgroup of patients with underlying ischemic heart 
disease; liberal transfusion strategy was 3% and in the restrictive transfusion strategy was 12% 
(difference =10.7%; 95% confidence intervals -9.8 to 31.2; interaction p=0.11)  
Variation in Transfusion and Guidelines : The systematic reviews of observational studies and 
randomized  trials  evaluating  the impact  of anemia  and transfusion  highlight  the lack of  any study  with 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 17  
  
sufficient numbers of patients to guide clinical care. All of this uncertainty has helped fuel significant 
practice variation.  Two older large studies in 44,242 patients with non -ST segment elevation 
myocardial infarction from 400 US hospitals(9) and 17,676 patients with acute myocardial infarction 
demonstrate substantial variation in transfusion.(10) Similar variation was observed in over 19,315 
hospitalized patients with a discharge diagnosis of myocardial infarction during 2009 -2012 from the 
California  Kaiser  Permanente  Health  System  (Percent  transfused  at nadir  hemoglobin  level >10 g/dL, 
0.2%; 9 -9.9 g/dL, 12.5%; 8 -8.9 g/dL, 48.9%; 7 -7.9 g/dL, 78.3%; < 7 g/dL, 91.5%). (39)  A significant  
proportion of patients had transfusion thresholds at every cut -off from 7 to 10 g/dL. An updated 
analysis demonstrates variation in hospital acquired anemia in 17,676 patients with myocardial 
infarction (40) and transfusion among 34,937 patients with a myocardial infarction hospitalized 
between 2000 -2008 in 57 centers. (41)  In a retrospective cohort study based on the CathPCI 
Registry  data from 2009  to 2013,  the risk adjusted  rates  of transfusion  by hospital  varied  from 0.3%  to 
9.3%.  (42) The high transfusion  hospitals  used  a threshold  between  9 to 10 g/dL, and  low transfusion 
hospitals used a threshold between 8 to 9 g/dL.  More contemporary data in cardiac surgery patients 
from 2013 show continued variation in transfusion practice. (43)  
The variation in transfusion practice may further be exacerbated by the great variability in the 
transfusion  guideline  recommendations.  While  all conclude  that there  are too few high-quality  studies, 
recommendations vary widely among organizations. The American Red Cross, AABB, British 
Committee for Standards in Haematology were not able to recommend a course of action,(44, 45) the 
American College of Physicians recommends 7 -8 g/dL in patients with heart disease but is silent in 
acute coronary syndrome patients;(46) the American College of Cardiology/American Heart 
Association suggests avoidance of transfusion unless hemoglobin less than 8 g/dL(47, 48); National 
Comprehensive Cancer Network recommends 10 g/dL threshold in patients with coronary heart 
disease including patients with acute coronary syndrome (49), National Blood Authority of Australia 
recommends 8 g/dL threshold (50), and the European Society of Cardiology recommends transfusion 
only in case of compromised hemodynamic status and hemoglobin less than 7 g/dL.(51) The recently 
published guidelines from the AABB concluded that there was insufficient evidence in patients with 
acute MI and did not provide a specific recommendation,  (52) while the UK National Clinical 
Guidelines Centre  recommended  transfusion  at 8 g/dL (53).  Given  the lack of high  quality  evidence  to 
guide transfusion in patients with acute myocardial infarction, it is not surprising that there is variation 
in recommendations emanating from different organizations.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 18  
 
CStudy  Objectives   
Despite the variation in guidelines for transfusion in patients with acute myocardial infarction, there 
has been  a strong  and consistent  trend  towards reducing  the use of blood  transfusion  in the US. For 
example, red blood cell transfusions per 1000 US population fell by 13.9% between 2013 and 2015.  
(54) Data  from California  Kaiser  Permanente  Health  System  show  that in 70,189  hospitalized  patients 
with cardiovascular disease, the  frequency  of transfusion fell 25% between 2009 and  2013. (55)  The 
pre-transfusion  hemoglobin  in patients  with cardiovascular  disease  declined  from 8.1 to 7.6 g/dL.  This 
change in clinical practice may be due to the widespread implementation of blood management 
programs (54) and Choosing Wisely Campaigns which targeted “unnecessary” transfusions. (56)  
B2 Rationale  for this Study:  Equipoise  
Every day, clinicians encounter anemic patients who have acute ischemic heart disease where a 
decision to transfuse must be made.  However, clinicians do not know what to do because:  1) 
Observational studies and randomized trials have come to different conclusions and are flawed; 2) 
Pathophysiological arguments  can be made  for liberal and  restrictive strategies; 3) Some  clinical trials 
in other settings suggest  a restrictive transfusion approach is safe but other trials signal  the possibility 
of reduced mortality with liberal transfusion in patients with cardiac disease; 4) Guidelines provide 
conflicting  advice.  This has led to practice  variation(9,  57) and confusion  in the clinical  community  with 
no clear guidance on when to transfuse.  Thus, the NHLBI State of the Science expert panel 
concluded in March 2015 “equipoise  for transfusion thresholds persists  in patients with ischemic heart 
disease.” (58) The ACC/AHA guidelines for management of STEMI concluded, “the optimal 
hemoglobin level in the transfused patient is not known.”(47, 48)  Furthermore, the recently published 
guidelines by the AABB identified acute coronary syndrome as clinical setting where the evidence is 
“judged to be insufficient” to recommend transfusion threshold.(16) Based on these findings and 
existing data there clearly is equipoise. For all these reasons, a high quality randomized trial to guide 
transfusion is urgently needed to answer this clinically relevant question.  
 
C1 Primary  Aim 
The primary aim is to determine whether a liberal transfusion strategy with a threshold of 10 g/dL 
reduces the composite outcome of all -cause mortality or nonfatal myocardial reinfarction through 30 
days  following  randomization,  compared  to a restrictive  transfusion  strategy with  a threshold  of 7 to 8 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 19  
  
g/dL among patients  with an acute  myocardial  infarction  and a hemoglobin  concentration  less than 10 
g/dL.  
C2 Secondary  Aims  
1) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  reduces all -cause  mortality 
within 30 days, compared to a restrictive transfusion strategy.  
2) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  reduces  myocardial  reinfarction 
within 30 days, compared to a restrictive transfusion strategy.  
3) To determine whether a liberal (10g/dL) transfusion strategy reduces the composite 
outcome of all -cause mortality, nonfatal myocardial reinfarction, ischemia driven unscheduled 
coronary  revascularization  (percutaneous  coronary  intervention  or coronary  artery  bypass  grafting),  or 
readmission to the hospital for ischemic cardiac diagnosis within 30 days, compared to a restrictive 
transfusion strategy.  
C3 Tertiary  Aims  
1) To determine whether a liberal (10g/dL) transfusion strategy reduces all -cause mortality, 
nonfatal  myocardial  reinfarction,  or unstable  angina  (i.e. acute  coronary  syndrome)  within  30 days, 
compared to a restrictive transfusion strategy.  
2) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  reduces  ischemia  driven 
unscheduled coronary revascularization within 30 -days compared to a restrictive strategy.  
3) To determine whether a liberal (10g/dL) transfusion strategy reduces unscheduled 
readmission  to hospital  for ischemic  cardiac  diagnosis  within  30 days,  compared  to a restrictive 
strategy.  
4) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  increases  congestive  heart 
failure within 30 days, compared to a restrictive transfusion strategy.  
5) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  reduces  unscheduled 
readmission to hospital for any reason within 30 days, compared to a restrictive strategy.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 20  
  
6) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  increases  each  of the 
individual  thrombotic/hemorrhagic outcomes  of stroke, pulmonary  embolism  or deep  venous 
thrombosis, and bleeding within 30 days, compared to a restrictive strategy.  
7) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  increases  each  of the 
individual  infectious  outcomes of pneumonia,  blood  stream, and  urinary  tract within  30 days, 
compared to a restrictive strategy.  
8) To determine  whether  a liberal  (10g/dL)  transfusion  strategy  reduces  each  of the  individual 
in-hospital outcomes of length of hospital stay post randomization and number of days in intensive 
care unit, compared to a restrictive strategy.  
9) To determine whether a liberal (10g/dL) transfusion strategy increases patient reported 
quality  of life  using  the EuroQol  questionnaire  (EQ-5D) at 30  days compared  to a restrictive  strategy  
10 To determine  whether  a liberal  (10g/dL)  transfusion  strategy  reduces  all-cause  mortality  at 6- 
months following randomization, compared to a restrictive strategy.  
C4 Rationale  for the Selection  of Outcome  Measures  
The study outcomes assess the clinically important benefits and harms of transfusion and anemia in 
vulnerable individuals with compromised myocardium. Blood transfusions may decrease ischemic 
injury and improve myocardial performance by improving oxygen delivery to the myocardium in high - 
risk patients. However, transfusions may also harm patients. Blood transfusions acutely increase 
blood  volume  in patients  who may not adapt  rapidly  enough  resulting  in increased  rates  of pulmonary 
edema and heart failure. The increased blood volume could also lead to higher risk of bleeding from 
increased intravascular pressure.  Blood transfusion is also associated  with immunosuppression and 
may lead to infection.  In addition, laboratory  data suggest  that transfusions  may not enhance  oxygen 
delivery and may be associated with increased platelet aggregation.  
If transfusion to maintain the hemoglobin concentration >10 g/dL does mitigate the clinical 
consequences of anemia in ischemic cardiac injury, there will be a reduction of mortality and 
reinfarction.  Higher hemoglobin concentrations might also reduce other sequelae of decreased 
oxygen  delivery  to the myocardium; unscheduled  coronary  revascularization,  hospital  readmission  for 
ischemic symptoms, unstable angina, and cardiovascular mortality.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 21  
 
DStudy  Design   
On the other hand, if transfusion results in clinically important fluid overload, immunosuppression, 
increased viscosity, and inflammation there will be an increase in congestive heart failure, infection, 
bleeding,  stroke,  and pulmonary  embolism  or deep  venous  thrombosis.  Each  of these  may contribute 
to death or reinfarction.  
Higher  hemoglobin  levels  may also be associated  with a more positive  feeling  of well-being  and a 
better perceived quality of life as measured by the EQ -5D. 
Outcomes  are assessed  at 30 days  since  blood  transfusion  will have  its maximum effect  within  this 
time period.  Mortality will also be assessed at 6 months to determine if early effects of blood 
transfusion persist.  
 
D1 Overview  or Design  Summary  
This is a randomized, unblinded, two group multicenter clinical trial.  Eligible study patients are 
randomized to receive either the liberal or the restrictive transfusion strategy.  Transfusion strategy 
assignment  is not blinded.  The transfusion  protocol is  followed  during the  Index  hospitalization  (for up 
to 30 days).  Each patient will be contacted at 30 days to ascertain study outcomes and at 6 months 
when vital status will be verified.  The 30 -day and 6 -month follow -ups will be administered by 
telephone, but  the follow -up questions could  be administered  in person,  for example,  if the  patient  is in 
the hospital during the follow -up window.  During the 30 -day follow -up, readmissions to the hospital 
that have occurred within the 30 days are identified and medical records will be obtained. The Clinical 
Events Committee, masked to treatment allocation, will adjudicate occurrences of myocardial 
infarction within the 30 -day window.  
Each of the transfusion strategies in this trial is routinely used in current medical practice.  Study 
patients will be followed while they are in the hospital (for up to 30 days) during which time 
hemoglobin  levels,  cardiac  biomarker  of necrosis  levels,  electrocardiograms,  and number  of units  of 
red blood cell transfusions administered will be collected.  
The transfusion  strategies  will be compared  for differences  in mortality,  cardiac  events  and other 
important morbidity, hospital re -admissions, and patient perceived quality of life.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 22  
  
The goal of this  study  is to determine  whether  a liberal  transfusion  strategy  is superior  to a restrictive 
strategy in anemic patients with acute myocardial infarction.  
D2 Subject  Selection  and Withdrawal  
 
2.a Inclusion  Criteria  
The eligible  study  population  includes  patients  who meet all  of the following  criteria: 1)  18 years  of age 
or older; 2) with either ST segment elevation myocardial infarction or Non ST segment elevation 
myocardial infarction consistent with the 3rd Universal Definition of Myocardial Infarction criteria (38) 
that occurs on admission or during the index hospitalization, 3) with a hemoglobin concentration less 
than 10 g/dL at the time of random allocation, and 4) the patient’s attending physician, with expertise 
in cardiovascular care, believes that both of the transfusion strategies are consistent with good 
medical care for the patient as determined by his/her clinical judgement.  
To simplify the diagnosis of acute myocardial infarction, we will require a rise in cardiac biomarker 
values  [preferably  cardiac  troponin  (cTn)]  with at least  one value above  the upper  reference  limit of 
normal of the hospital. We anticipate (and will confirm) that the hospital upper limit of normal for 
troponin will be equivalent to or above the 99th percentile upper reference at all hospitals.  
In addition to evidence of myocardial necrosis, we require patients to have at least one of the 
following: (1) symptoms of ischemia; (2) new/presumed new ST segment or T wave (ST -T) changes 
or new left bundle branch block (LBBB); (3) development of pathological Q waves; (4) imaging 
evidence of new loss of viable myocardium or new regional wall motion abnormality; and/or (5) 
identification of an intracoronary thrombus by angiography. (37)  We will include patients with Type 1 
(i.e., spontaneous MI presumably related to atherosclerotic plaque rupture, ulceration, fissuring, 
erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries, 
leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis), 
Type  2 (i.e., secondary  to an ischemic  imbalance  such  that myocardial  injury  with necrosis  occurs  due 
to myocardial oxygen supply and/or demand mismatch),Type 4b (i.e., stent thrombosis at 
angiography), and  Type 4c (i.e., severe in -stent restenosis without evidence of thrombus).  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 23  
  
2.b Exclusion  Criteria  
Patients will be excluded if any of the following criteria are met 1) uncontrolled acute bleeding at the 
time of randomization defined as the need for uncrossed or non -type specific blood; 2) decline blood 
transfusion; 3) scheduled for cardiac surgery during the current admission; 4) are receiving only 
palliative treatment; 5) if known that follow -up will not be possible at 30 days; 6) if previously 
participated  in MINT 7)  if currently  enrolled  in a competing  study  that interferes  with the intervention  or 
follow -up of MINT or enrolled in a competing study that has not been approved by the local IRB; or 8) 
if the attending physician does not believe the patient is an appropriate candidate for the trial for any 
reason.  
Patients  who have  had an episode  of uncontrolled  bleeding  may be enrolled later  if the hemoglobin 
remains below 10 g/dL, they are no longer actively bleeding, and they are otherwise still eligible.  
2.c Ethical  Considerations  
Both transfusion strategies assessed in this trial are widely used in clinical practice.  There is 
uncertainty about which strategy is better, and therefore there is clinical equipoise to conduct this 
study.  Furthermore,  at the time of recruitment,  the investigator  will request  permission  of the patient’s 
doctor to seek the patient’s consent and randomly allocate them to one of the transfusion arms.  
At the time consent is obtained, the clinical site study staff will also request the names and contact 
information  of two additional  individuals who  may be contacted  in the event study  staff are not able to 
reach the patient directly at the follow -up time points.  This will minimize loss to follow -up. This 
information will be retained at the clinical site and destroyed at the end of the trial.  
2.d Randomization  Method  and Blinding  
The Data Coordinating Center (DCC) will prepare the randomization schedules. Allocation of the 
transfusion intervention strategies will be in a 1:1 ratio.  Given the diverse patient mix among 
participating  clinical  sites,  the randomization  will be stratified  by clinical  site, and a permuted  block 
design  with random  block  sizes  will be used  to balance  treatment  assignments  within  each  clinical 
site. 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 24  
  
Study  patients  and physicians  caring  for the patient cannot be  masked  to treatment  assignment  (i.e., 
administration of red blood cell transfusion). However, the central classification of the myocardial 
reinfarction component of the primary outcome is performed masked to assignment.  
2.e Subject  Recruitment  Plans  and Consent  Process  
The study recruits hospitalized patients diagnosed with acute myocardial infarction (Type 1, Type 2, 
Type 4b, or Type 4c).  Prior to study initiation, each cardiologist at the clinical site will be personally 
contacted by the clinical site principal investigator or coordinator and permission will be sought to 
recruit  patients  who are eligible  for the study.  Patients  of physicians  who do not wish to participate  in 
the trial will not be approached for recruitment.  
Study  staff will identify  potential  study  patients,  confirm  that the physician  agrees  that the patient  can 
be randomized into the study (see script in Appendix 1) and approach the patient for consent.  
Surrogate consent, in accordance with local IRB rules, will be sought for each eligible patient who is 
not able  to grant  consent. A  substantial  number  of patients  eligible  for this trial are likely  to be critically 
ill, medicated, and/or cognitively impaired and unable to grant consent.  It is essential that these 
patients be included as physicians routinely face the dilemma of whether or not they should be 
transfused.  
2.f Risks  and Benefits  
In patients with heart disease, risks and benefits are considerably different than most other patient 
populations.  Oxygen delivery to the myocardium is flow dependent since the heart extracts a high 
percentage of oxygen and myocardial ischemia may be precipitated or worsened by low hemoglobin 
concentrations, especially in patients with acute myocardial infarction.  Anemia, if untreated may 
result in increased risks of further myocardial ischemia and injury. Transfusions, on the other hand, 
may result in increased risks of pulmonary edema and heart failure (Transfusion -Associated 
Circulatory  Overload),  from the significant amounts of volume  given  to patients with  impaired  ability of 
the heart  to pump  (systolic  dysfunction)  or ability  to relax  and fill (diastolic  dysfunction).  Other  adverse 
effects of allogeneic blood transfusion were also a concern: immunologic (transfusion -related acute 
lung injury [TRALI],(59) and transfusion -related immune modulation [TRIM] possibly leading to 
increased bacterial infections).(60) Thus, there is clinical equipoise because it is unclear whether the 
benefits of immediate correction of anemia with transfusion are outweighed by the potential side 
effects of transfusion.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 25  
  
2.g Early  Withdrawal  of Subjects  from  Transfusion  Strategy  and Trial 
Procedures  
The study  participant  (i.e. patient)  can be withdrawn  from the transfusion  strategy  (liberal  or restrictive 
transfusion allocation) at any time, either at the request of the treating physician or the patient 
themselves.  The clinical site director may also withdraw a patient. Following the withdrawal, all 
transfusion decisions will be per treating physician.  The patient or physician may also request 
withdrawal from any trial procedure or follow -up. 
2.h When  and How  to Withdraw  Subjects  
There are few reasons why a patient or physician might want to withdraw from the trial.  If the patient 
has an adverse  effect  from a  prior transfusion or proves to be  difficult to cross match, the physician  or 
patient may choose to withdraw from the study.  However, the most common reasons are likely to be 
patient’s preference not to participate in research or desire not to have extra blood tests or be 
contacted for follow -up. If a concern is raised and a request for withdrawal is made by the patient or 
the physician, study staff will confirm the issue (e.g., transfusion strategy, study required 
measurements and/or telephone follow -up) and try to address the concern.  Study staff will be 
required  to contact the MINT CCC PI to  discuss  the individual situation.  If appropriate, the patient  will 
be given the opportunity  to refrain  from the objectionable study  procedure(s) and  remain in  the overall 
study. All efforts will be made to avoid a participant feeling unduly pressured to remain in the study. If 
no intermediate solution is acceptable to the patient and/or treating physician, the patient will be 
withdrawn from the study.  The study staff will document the date of withdrawal, any known reasons 
for withdrawal  and whether  the patient will  continue  with any of the study  procedures and/or  follow -up. 
All treating  physicians  will be immediately  notified  of a withdrawal  from the transfusion  strategy  (liberal 
or restrictive transfusion allocation).  
2.i Data  Collection  and Follow -up for Withdrawn  Subjects  
At the time of withdrawal, the study staff will request permission to continue with data collection and 
follow -up through  the 6-month  study  time window.  However, the  exact  amount  of follow -up performed 
will vary in accordance with the patients’ authorization.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 26  
  
D3 Trial  Transfusion  Strategies  
 
3.a Description  
We are comparing two commonly used approaches to transfusion therapy, both of which can be 
considered  as “standards  of care.” For  both strategies,  blood  must  be administered  one unit at a time 
followed by a hemoglobin measurement. The transfusion strategy will be followed throughout the 
index hospitalization up to 30 days, discharge, or death.  
3.b Transfusion  Strategies  
Restrictive Transfusion Strategy : Patients randomized to the restrictive transfusion strategy will be 
permitted to receive a transfusion if the hemoglobin concentration falls below 8 g/dL and will be 
strongly recommended to receive transfusion if the hemoglobin concentration is below 7 g/dL. 
Transfusion  is also permitted  if angina  symptoms  (i.e., retrosternal  chest  discomfort,  chest  discomfort 
described as pressure or heaviness) that are thought by the clinician to be related to anemia occur 
and are not controlled with anti -anginal medications (sublingual nitroglycerin or equivalent therapy). 
Blood will be administered one unit at a time and enough blood given to increase the hemoglobin 
concentration above 7 to 8 g/dL or to relieve symptoms of uncontrolled angina.  
Liberal Transfusion Strategy : Patients randomly allocated to the liberal transfusion strategy will  
receive  one unit of packed  red cells following  randomization  and will receive  enough  blood  to raise  the 
hemoglobin concentration to 10 g/dL or above any time the hemoglobin concentration is detected to 
be below 10 g/dL. A post transfusion hemoglobin measurement showing a hemoglobin level of at  
least 10 g/dL must be obtained.  
A patient in either group may be transfused at any time without a hemoglobin level if the patient is 
actively bleeding (e.g., brisk gastrointestinal bleeding) and the physician believes an emergency 
transfusion  is needed.  A patient  in either  group  with history  of congestive  heart  failure  or low ejection 
fraction may receive diuretics prior to or after transfusion.  
3.c Rationale  for Transfusion  Thresholds  
The restrictive  transfusion  group  reﬂects  many  current  guidelines  (including  European  guidelines)(51, 
61). A blood transfusion will be permitted in the restrictive group if the hemoglobin concentration is 
less than 8 g/dL. Discussions with many cardiologists suggested that many clinicians are not  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 27  
  
comfortable  with a threshold  as low as 7 g/dL (as  used  in TRICC);  however,  individual  clinicians  may 
choose to use  a threshold of less  than 7  g/dL to trigger transfusions.  Patients may  be transfused  for 
signs or symptoms when the clinician believes it is necessary although this did not occur in the pilot 
trial and was uncommon in the FOCUS trial which also incorporated symptoms in the restrictive 
transfusion protocol.  
In the liberal transfusion group, a threshold of less than 10 g/dL was chosen because oxygen delivery 
to the myocardium is flow dependent and myocardial ischemia may be precipitated or worsened by 
low hemoglobin concentrations in patients with coronary stenosis or active plaques.  Studies 
performed  in canines found electrocardiographic  changes  consistent  with ischemia as  high as 10  g/dL 
with experimentally induced coronary artery disease. Data from patients who decline blood  
transfusion  for religious  reasons were  congruent  with animal  data and found  the odds  of death  rose as 
the hemoglobin fell below 10 g/dL.  
3.d Method  for Assigning  Subjects  to Treatment  Groups  
Clinical site staff will obtain the randomly assigned transfusion strategy for each eligible consented 
patient using the  MINT website. The  randomization system  will be available via a secure  area of the 
MINT project website with access restricted to those clinical site personnel with permission to 
randomize patients.  Those who are certified to use the randomization system will be trained to 
adhere to a strict randomization protocol.  In particular, the clinical site personnel must confirm the 
patient’s eligibility status in the system before a transfusion strategy assignment is provided.  If the 
web-based  randomization  system  is not accessible,  clinical  site personnel  will be instructed  to follow 
back -up procedures in order to ensure that the clinical centers are able to randomize patient 24/7.  
3.e Preparation  and Administration  of Red Blood  Cell Transfusions  
All red blood cell units are maintained and ordered through the hospital blood bank.  The storage 
solution and storage time will be at the discretion of the blood bank, but only leukoreduced red blood 
cell transfusion will be used.  The transfusions are administered by hospital staff in accordance with 
hospital  policy.  Study  staff will  alert the nursing  and medical  staff to the assigned  transfusion  strategy 
each time a new  patient has been enrolled in the  study. Treating staff will order (or not order) red cell 
transfusions in accordance with the protocol.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 28  
  
3.f Subject  Compliance  Monitoring  
There  are two primary  site based  mechanisms  to ensure  adherence  to the assigned  transfusion 
strategy 1) study staff review  of the medical record and, if necessary, direct discussion with the 
treating physicians and, 2) direct assistance from the blood bank.  
The clinical site is to obtain a daily hemoglobin level for each randomized patient for the first three 
days following randomization (or through hospital discharge, if sooner). Additional hemoglobin levels 
are measured as clinically indicated.  Study staff will closely monitor each patient to ensure that each 
of the required hemoglobin levels are drawn, review the results, and confirm that the transfusions 
have been ordered (or not ordered) in accordance with the transfusion assignment.  If there is a 
hemoglobin value that should trigger a transfusion and none is ordered or, as the alternative, a 
transfusion ordered without a hemoglobin value to trigger the transfusion, study staff will discuss the 
case with the treating physician.  Likewise, if a required hemoglobin level has not been ordered, the 
study  staff will alert the physician.  The required  hemoglobin measurements  are of primary  importance 
to verify that patients in the liberal strategy maintain a level of at least 10 g/dL.  
The clinical  site will also request assistance  from the blood bank  to help prevent protocol  violations in 
the restrictive strategy.  Study staff will notify the blood bank each time a patient is assigned to the 
restrictive strategy and request notification prior to the release of any red blood cell transfusions that 
are ordered.  The study staff will then review the medical record to verify that the transfusion is in 
accordance with the protocol.  If administration of blood is a violation of the protocol, study staff will 
contact  the ordering physician  to discuss  transfusion  plans  and to clarify  the study  protocol.  However, 
study staff do not approve or disapprove the transfusion. The final decision on the transfusion is 
always the treating physician’s.  
Study wide, the DCC will centrally monitor transfusions and hemoglobin levels on an ongoing basis. 
Transfusion  rates  for each  strategy  will be measured  overall  and by clinical  site. Specifically, the  DCC 
will identify  instances  when  1) patients  randomized  to the liberal  strategy  do not receive  a transfusion,  
2) patients  randomized  to the liberal  strategy  are discharged  with a hemoglobin  level < 10 g/dL and, 
3) patients  randomized  to the restrictive  strategy  without  anginal  symptoms  and a hemoglobin  level ≥ 
8 g/dL receive a transfusion. Reports of the protocol violations will be prepared by the DCC. The 
Clinical Coordinating Center (CCC) will review these reports and discuss as necessary with the 
clinical sites.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 29  
 
EStudy  Procedures   
3.g Prior  and Concomitant  Therapy  
Transfusion prior to randomization is at the discretion of the clinicians.  An otherwise eligible patient 
may be randomized  as long as the hemoglobin  level is <10g/dL,  regardless  of prior transfusions at  the 
time of randomization.  Once the patient has been randomized all red cell transfusions are 
administered per the study protocol.  The protocol will not control the administration of other blood 
products including platelets or fresh frozen plasma. Similarly, it will not mandate specific medical or 
procedural treatments to manage these patients.  
3.h Blinding  of Study  Intervention  
Due to the nature of the interventions, study patients and physicians caring for the patients cannot be 
blinded  to transfusion  assignment.  However,  transfusion  strategy  assignment  will be concealed  during 
the central classification of the myocardial reinfarction component of the primary outcome.  
 
E1 Screening  for Eligibility  
Several  approaches  to screening  for study  patients will  be used.  Study  staff will  review  the results  of 
all troponin levels daily.  Medical records for patients with values above the upper reference limit of 
normal are reviewed and assessed  for eligibility. Study staff will screen all admissions to the cardiac 
care unit, and scheduled for cardiac catheterization. The physician of each eligible patient with a 
hemoglobin level <10 g/dL will be contacted to confirm that the patient can be entered into the trial 
using  a standardized  script  (Appendix  1), and consent  will be sought.  Study  staff will follow  otherwise 
eligible patients with hemoglobin levels ≥ 10 g/dL and consent the patient if the hemoglobin level 
drops to the entry level.  
E2 Schedule  of Measurements  
Each randomized patient is required to have hemoglobin levels, troponin levels, and 
electrocardiogram  readings  at specified  time points  (while  in the hospital).  The blood  samples  will 
normally be drawn with the daily morning blood phlebotomy.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 30  
  
The required time points for hemoglobin levels  are: 1) within 24 hours prior to randomization 
(eligibility  hemoglobin  level),  2) day 1 post randomization,  3) day 2 post randomization,  4) day 3 post 
randomization.  
The required  time points  for the troponin  levels  are: 1) within  24 hours  prior to randomization, 2)  12 
hours following randomization, 3) day 1 post randomization, 4) day 2 post randomization, 5) day 3 
post randomization.  
The required  time points  for the ECGs  are: 1)  within  24 hours  prior to randomization, 2)  day 1 post 
randomization, 3) day 2 post randomization, 4) day 3 post randomization.  
A listing  of the types  of data elements  that will be collected  at each  time point  is presented  in 
Appendix 2.  
E3 In-hospital  Follow -up 
Study staff will review the medical records and follow participants during the hospitalization, for up to 
30 days post randomization. They will carefully follow and document hemoglobin levels and 
transfusion  status  to assure  that the transfusion  protocol  is being  followed.  In addition, during  the first 
3 days following randomization they will confirm that each of the required cardiac biomarkers for 
necrosis, hemoglobin levels, and electrocardiograms has been ordered and the results are recorded.  
At 30 days post randomization, or hospital discharge if sooner, the study staff will complete and 
submit  all study  data related  to the hospitalization  including baseline  health  status,  laboratory  results, 
post randomization events and copies of all electrocardiograms performed.  
E4 Follow -up at 30 Days  
Study staff at the clinical sites will contact each patient at 30 days following randomization.  In 
general, the 30 -day follow -up will be administered by telephone, but the follow -up questions could be 
administered in person.  The follow -up interview will include questions about the patient’s health and 
quality  of life  during  the follow -up interval  and will determine  if there  have  been  any re-admissions  to a 
hospital within 30 days of randomization.  Local site staff will obtain the hospital records for each re - 
admission.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 31  
  
There will be a 30 -day window (from 30 days to 60 days following randomization) for study staff to 
obtain  the 30-day follow -up information.  In the event  they are not able  to contact  the patient directly, 
they will try to reach the alternate contacts that have been provided, and a letter will be sent to the 
patient if needed.  
E5 Follow -up at 6 Months  
Study staff at the clinical sites will perform a final follow -up contact at 6 months following 
randomization  to determine  the patient’s  vital status.  There  will be a 30-day window  (from  180 days  to 
210 days  following randomization)  to obtain  the 6-month  information.  In the event that  study  staff are 
not able to contact the patient at the 6 -month time point, they will follow the same procedure outlined 
at the 30 -day follow -up. 
E6 Safety  and Adverse  Events  
 
6.a Safety  and Compliance  Monitoring  
The DCC will monitor key aspects of protocol compliance, and reports will be developed and 
disseminated to monitor the ongoing progress of the study.  Protocol safety and compliance reports 
will include enrollment of ineligible patients, follow -up data collection outside of protocol -defined 
windows, deviations from the protocol, and adherence to established adverse event reporting and 
event  adjudication  procedures.  Reports  will be provided  to the CCC,  the Steering  Committee,  and the 
DSMB on a systematic basis.  
6.b Medical  Monitoring  
The DCC  is responsible  for tracking  the Serious  Adverse  Events  (SAEs)  reported  by clinical  sites in 
the MINT trial.  The DCC will track the time for each step of the process to ensure that turnaround 
times  adhere  to acceptable  reporting  practices  specified  by the FDA and NIH. The current  reporting 
guidelines from NHLBI ( https://www.nhlbi.nih.gov/research/funding/human -subjects/adverse -event ) 
will be followed, and the timelines are included in Appendix 3.  
i Investigator  Only  
The clinical  site will submit a  SAE form to the DCC  for unexpected  serious  adverse events  occurring 
within 30 days of randomization and for unexpected deaths occurring within 6 months of  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 32  
  
randomization.  The clinical sites are responsible for notifying their local Institutional Review Board. 
Expected  SAEs  will be reported  on the standard  MINT in -hospital  and follow -up data collection  forms.  
ii Independent  Expert  to Monitor  
The DCC  will notify  the MINT Medical  Safety  Officer of unexpected  SAEs  submitted  by a clinical  site 
and make  the relevant  information  available  to the officer.  The Medical  Safety  Officer  will determine  
a) the severity of the event, b) the unexpectedness, and c) the relatedness to the study protocol.  In 
accordance with safety reporting regulations, all SAEs that are determined by the Medical Safety 
Officer  to be both unexpected and  possibly, probably  or definitely related  to the  study  protocol will be 
subject to expedited reporting to the Data and Safety Monitoring Board (DSMB), NIH, and any other 
oversight entities as appropriate.  The NIH Project Officer and the DSMB chairperson will review 
these  documents  and may decide  to convene  the DSMB  to discuss  issues  related  to monitoring  such 
events.  
iii Independent  Data  and Safety  Monitoring  Board  
An external Data and Safety Monitoring Board (DSMB) consisting of members appointed by the 
National Heart, Lung, and Blood Institute (NHLBI) will monitor the study, advise the NIH Program 
Office and provide input to the Steering Committee.  The MINT DSMB will include experts in 
cardiology, transfusion medicine, biostatistics and ethics.  The DSMB will review the study protocol 
and provide  NHLBI  with recommendations  including  whether  the protocol  and patient  recruitment  can 
be initiated.  NHBLI will approve the study protocol based on the DSMB recommendations before 
patient recruitment is initiated. Throughout the course of the trial, the Data and Safety Monitoring 
Board (DSMB) will review recruitment, retention, data completeness, and protocol deviations on a 
semi -annual basis and will provide recommendations to NHLBI.  
Adverse events will be monitored in four distinct ways: 1) the DSMB will review all reported adverse 
events and monitor the incidence rates of adverse events on a semi -annual basis, 2) the expedited 
review of unexpected Serious Adverse Events (SAE) that are related to the MINT protocol and 
unanticipated problems (UP), 3) all study  outcomes will be evaluated by  assigned  treatment  group  on 
semi -annual  basis,  and 4) a formal  statistical  interim  monitoring  of the efficacy  of the primary  outcome 
by assigned treatment group will be performed on an annual basis.  If unexpected safety concerns 
arise from the trial data or from external research or literature, safety data will be examined on an ad 
hoc basis. The DCC will work with the NIH and with the DSMB to make certain that the board  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 33  
  
members  have  sufficient  information  to comprehensively  monitor  patient  safety  throughout  the MINT 
trial. The DSMB may advise early termination of the trial for safety reasons or make other 
recommendations regarding modifications to the protocol.  
In order to ensure that the MINT trial has adequate power to test its primary aims, the DSMB will 
review  an interim  sample  size/power  analysis  after half of the patients  complete  the 30-day follow -up. 
Revised sample size estimates will be calculated based on the observed overall event rate (i.e. the 
two transfusion groups combined) and the proposed power and effect size.  
6.c Definitions  of Adverse  Events  
An adverse event is defined as an untoward or unfavorable medical occurrence in a human 
participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), 
symptom , or disease, temporally associated with a person’s participation in the research, whether or 
not considered  related  to a person’s  participation  in the research.  A Serious  Adverse  Event (SAE)  is 
defined as an adverse event that meets any of the following criteria:  
• results  in death;  
• is life-threatening  i.e. places  a participant  at immediate  risk of death  from the event  as it 
occurred;  
• requires  inpatient  hospitalization  or prolongation  of existing  hospitalization;  
• results  in a persistent  or significant  disability/incapacity;  
• results  in a congenital  anomaly/birth  defect;  OR 
• any other  adverse  event  that, based  upon  appropriate  medical  judgment,  may jeopardize  the 
participant’s health and may require medical or surgical intervention to prevent one of the 
other outcomes listed in this definition.  
 
An Unanticipated  Problem  (UP) is defined  as any incident,  experience,  or outcome  that meets  all of 
the following criteria:  
• Unexpected  in terms  of nature,  severity,  or frequency,  taking  protocol  research  procedures 
and participation population characteristics into consideration.  
• Related  or possibly  related  to a person’s  participation  in the research.  
• Places  participants  or others  at a greater  risk of harm  (including  physical,  psychological, 
economic, or social harm) than was previously known or recognized.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 34  
  
6.d Classification  of Events  
 
i Severity  
The severity of the adverse event refers to the intensity of an event and is categorized as 1) Mild; 
asymptomatic or  mild symptoms; clinical  or diagnostic  observations  only; intervention  not indicated, 2) 
Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental 
activities of daily living, 3) Severe or medically significant but not immediately life -threatening; 
hospitalization  or prolongation  of hospitalization  indicated;  disabling;  limiting  self-care activities  of daily 
living, 4) Life -threatening consequences; urgent intervention indicated, 5) Death related to AE.  
ii Relationship  
Relatedness refers to the extent to which an adverse event is considered to be related to the 
intervention or study procedures. An adverse event is considered related if there is a reasonable 
possibility  that the  event  may have  been  caused  by the procedure.  Note  that the term “suspected ” is 
also means possibly, probably or definitely related to the intervention or study procedures.  
The following  definitions  apply  to relatedness:  
1. Unrelated  
• Adverse  event  is clearly  due to extraneous  causes  (e.g.,  underlying  disease,  environment)  
 
2. Unlikely  (adverse  event  must  meet  2 of the following):  
• Does  not have  temporal  relationship  to intervention  
• Could  readily  have  been  produced  by the participant’s  clinical  state  
• Could  have  been  due to environmental  or other  interventions  
• Does  not follow  known  pattern  of response  to intervention  
• Does  not reappear  or worsen  with reintroduction  of intervention  
 
3.  Possible  (adverse  event  must  meet  2 of the following):  
• Has a reasonable  temporal  relationship  to intervention  
• Could  not readily  have  been  produced  by the participant’s  clinical  state  
• Could  not readily  have  been  due to environmental  or other  interventions  
• Follows  a known  pattern  of response  to intervention  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 35  
  
 
4. Probable  (adverse  event  must  meet  3 of the following):  
• Has a reasonable  temporal  relationship  to intervention  
• Could  not readily  have  been  produced  by the participant’s  clinical  state  or have  been  due to 
environmental or other interventions  
• Follows  a known  pattern  of response  to intervention  
• Disappears  or decreases  with reduction  in dose  or cessation  of intervention  
 
5. Definite  (adverse  event  must  meet  4 of the following):  
• Has a reasonable  temporal  relationship  to intervention  
• Could  not readily  have  been  produced  by the participant’s  clinical  state  or have  been  due to 
environmental or other interventions  
• Follows  a known  pattern  of response  to intervention  
• Disappears  or decreases  with reduction  in dose  or cessation  of intervention  and recurs  with re- 
exposure  
 
iii Expectedness  
An unexpected event is one that has not been documented previously as an established adverse 
reaction  to the study  intervention and that is not recognized as part of the  natural progression of the 
disease.  A particular  event  may also be considered  unexpected  if it has a higher  severity  grade  than 
what has been documented or identified previously.  
6.e Data  Collection  Procedures  for Adverse  Events  and Unanticipated 
Problems  
The clinical  site staff will report all  serious  adverse  events  and unanticipated  problems  on the trial data 
collection forms.  These events include those related to red blood cell transfusion including those 
specified in the informed consent form and those that are related to recent myocardial infarction.  All 
of the expected SAEs are recorded on the in -hospital and the 30 -day follow -up data collection  
forms.  Site personnel are required to report and document all unexpected SAEs and unanticipated 
problems to the DCC. The DCC will send all unexpected SAEs (as reported by the site) to the study 
Medical  Monitor  for final assessment  of severity,  relatedness,  and expectedness.  The Medical  Monitor 
will remain masked to the transfusion strategy while making his/her evaluation of the SAE.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 36  
  
6.f Reporting  Procedures  
All reported  SAEs  and unanticipated  problems  will be included  in systematic  reporting  to the DSMB  on 
a semi -annual basis. This includes adverse events and problems previously transmitted through 
expedited reporting.  
The following three classes of events need to be reported to the NHLBI, the DSMB and the Local IRB 
in an expedited manner:  1) Fatal or life  threatening unexpected suspected  SAE, 2) Non -fatal, non -life 
threatening unexpected suspected SAE, and 3) Unanticipated problem. Fatalities that are related to 
blood transfusions must also be reported to the FDA within 7 days according to the guidelines 
(http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/B  
lood/ucm074947.htm ). 
The site personnel will compete and submit a SAE form to the DCC within 72 hours of learning of the 
event whenever the event is both serious and unexpected.  In cases where the event is not serious 
but places the patient at greater risk of physical, psychological, economic, or social harm, and is both 
unexpected and related to the study, the site PI will fill out an Unanticipated Problem form within 14 
days of learning about the problem.  SAE forms are  forwarded along with relevant patient history data 
to the Medical  Monitor  for review. The  study  Medical  Monitor will  assess  the severity,  relatedness,  and 
expectedness of the event within 48 hours.  Following the Medical Monitor’s feedback on the 
expectedness and relatedness of the SAE, the DCC will complete an SAE report categorized as 
serious, unexpected and related.  A report will also be sent for unanticipated problems. The DCC will 
send the reports to the NHLBI DSMB Executive Secretary and the NHLBI Medical Monitor for review. 
All reporting (from the time that the Site learns about the event until it is reported to the NHLBI,  
DSMB, FDA and IRBs) will follow the NHLBI DSMB established timelines as specified in 
(https://www.nhlbi.nih.gov/research/funding/human -subjects/adverse -event ) as shown in Appendix 3. 
If other SAEs are noted  to occur  with abnormally  high frequency  during the trial, these will be reported 
promptly by the MINT DCC to the DSMB, and the NHLBI DSMB Executive Secretary and the NHLBI 
Medical Monitor.  Upon receipt of an expedited report, the DSMB chair will decide whether the event 
should be discussed at the next scheduled DSMB meeting or discussed  as soon as possible at an ad 
hoc meeting.  
IRB actions  regarding  the MINT  trial will be communicated  to the NHLBI  Project  Officer  and NHLBI 
Executive Secretary in an expedited fashion.  If the IRB or ethics board at any MINT site, CCC or  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 37  
  
DCC takes action regarding the MINT trial (e.g., the IRB places a hold on the trial or suspends the 
trial), the site will report this to the CCC within 24 hours of the action.  This will be communicated by 
telephone  and with an urgent  help desk  ticket  through  the MINT  trial data management  system.  The 
Site will submit written  documentation  from the IRB, an  explanation  of the  circumstances,  and a plan 
of action to the CCC within 72 hours.  The CCC will promptly communicate this information to the 
DCC and the NHLBI project officer.  The DCC is responsible for notifying and the NHLBI Executive 
Secretary.  A written  report  describing  the IRB decision, the  rationale  for the decision  and the plan of 
action  based  on this decision  will be submitted  to the NHLBI  project  officer  and the NHLBI  Executive 
Secretary within 7 days of the IRB action.  
6.g Adverse  Event  Reporting  Period  
All randomized patients will be followed by the trial for 30 -days from randomization, and vital status 
will be ascertained  at 6 months  from study  enrollment.  Serious  adverse  events  that occur  during  the 
30-day time period and all deaths up to 6 months will be reported.  
6.h Post -study  Adverse  Event  
MINT  will not collect  or report  information  about  adverse  events  that occur  more  than 30 -days  after 
randomization with the exception of death which will be reported through 6 months after 
randomization.  Reporting of Adverse events will cease at the conclusion of the MINT trial.  
E7 Study  Outcome  Measurements  and Ascertainment  
 
7.a Definitions  of Outcomes  
 
i Myocardial  Reinfarction  
Myocardial reinfarction will be classified by the Clinical Events Committee using The Joint European 
Society of Cardiology/American College of Cardiology Committee definitions. (47) Patients with 
reinfarction  will need  to demonstrate  a fall in the troponin  value  and then a subsequent  rise of at least 
20% with additional evidence (new ECG changes, imaging evidence, clinical history) as in the MI 
definition to  diagnose a  new event. Myocardial reinfarction will be classified as ST -segment  elevation 
or non -ST Segment elevation.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 38  
  
ii Death  and Cause  of Death  
For each  death,  the cause will be determined by  the site personnel into one of three categories  (47): 
cardiovascular death (e.g., congestive heart failure, dysrhythmia), noncardiovascular death (e.g., 
infection,  cancer),  or undetermined  cause  of death.  Information  about  the specific  cause  of death  will 
also be collected.  
iii Unscheduled  Coronary  Revascularization  (unstaged)  
Ischemia driven, unscheduled coronary revascularization (coronary artery bypass surgery or PCI) 
within 30 days of randomization will be recorded by the sites. Prior to randomization, the site will 
record  if a coronary  revascularization  is planned  (staged).  All coronary  revascularization  procedures 
will be recorded, but an elective planned staged procedure will not be included as an outcome.  
Information  about  the reason  for the procedure  will also be collected  to ensure that  the 
revascularization was done to treat ischemic heart disease.  
iv Readmission  to Hospital,  overall  and for primary  cardiac  diagnosis  
All re-admissions  to the hospital  that had  not been  planned  prior to randomization  will be captured, 
and the primary diagnosis for each hospitalization will be classified as: ischemic cardiac diagnosis 
(e.g.,  myocardial  infarction,  unstable  angina),  non-ischemic  cardiac  diagnosis  (e.g. heart  failure)  or 
non-cardiac.  
v Unstable  Angina  
The MINT trial sites will use 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular 
Endpoint Events in Clinical Trials to define unstable angina. (47) To diagnose unstable angina 
requires  that four criteria  be met: 1) worsening  ischemic  discomfort,  2) unscheduled  hospitalization,  
3) negative  cardiac  biomarker,  4) objective  evidence  of myocardial  ischemia.  
 
vi Congestive  Heart  Failure  
Sites personnel will use 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular 
Endpoint  Events  in Clinical  Trials  to define  congestive  heart failure.  (47) New or worsening  symptoms 
of congestive heart failure on presentation (increasing dyspnea, paroxysmal nocturnal dyspnea, 
orthopnea), has objective evidence of new or worsening heart failure, and receives initiation or 
intensification of treatment specifically for heart failure.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 39  
  
vii TIA or Stroke  
The 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in 
Clinical Trials will be used to define stroke. (47) A transient ischemic attack (TIA) is defined as “a 
transient  episode  of focal  neurological  dysfunction  caused  by brain,  spinal  cord,  or retinal  ischemia, 
without acute infarction.”  Stroke is defined on the basis of the presence of acute infarction as 
demonstrated by imaging or based on the persistence of symptoms more than 24 hours.  
viii Deep  Venous  Thrombosis  or Pulmonary  Embolism  
Deep  vein thrombosis  will be diagnosed  if duplex  ultrasound,  magnetic  resonance  venogram  (MRV), 
or venogram is definite or probable positive. Site investigators will record if location is proximal or 
distal. Pulmonary  embolism will be diagnosed  with a high probability  ventilation perfusion lung scan, 
CT scan, or pulmonary angiogram.  
ix Bleeding  
Major bleeding will be defined  as 1) fatal bleeding, and/or 2) symptomatic  bleeding in a  critical area  or 
organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra - articular or pericardial, or 
intramuscular with compartment syndrome, and/or 3) bleeding causing a drop in hemoglobin 
concentration of 2 g/dL or greater (62) from the last hemoglobin concentration prior to randomization 
to the nadir  hemoglobin  concentration  during  hospitalization  or up to 30 days  post randomization.  The 
drop in hemoglobin concentration will account for  each unit of red blood cell transfusion transfused by 
subtracting 1 g/dL for each unit administered.  
x Infections  
 
x.1 Pneumonia  
Pneumonia  will be diagnosed  using  CDC  criteria  (48) which includes  radiographic  abnormalities  and 
combination of symptoms (i.e.,  cough),  signs  (i.e., fever, tachypnea, or laboratory  abnormalities  (i.e., 
white blood cell count, hypoxemia).  
x.2 Blood  Stream  Infection  
Blood stream infection will be defined using CDC criteria which includes a recognized pathogen 
cultured  from 1 or more  blood  cultures  and organism  cultured  from blood  is not related  to an infection 
at another site, at least 1 of the following signs or symptoms: fever, chills, or hypotension and signs  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 40  
  
and symptoms and positive laboratory results are not related to an infection at another site and 
common  skin contaminant  is cultured  from 2 or more  blood  cultures  drawn  on separate  occasions.  
x.3 Urinary  Tract  Infection  
Urinary  Tract  Infection  will be defined  using CDC  criteria  (48) which  include  one of the following signs 
or symptoms: fever (>38.0°C) or localized pain or tenderness, and laboratory evidence for infection.  
xi Length  of Stay  and Intensive  Care  Unit Days  
The trial will collect  the number  of days  post randomization  that patient is  in the hospital  and in 
intensive care unit.  
xii Quality  of Life 
The EuroQol questionnaire (EQ -5D), a standardized instrument that measures health related quality 
of life  in 5 dimensions:  mobility,  self-care,  usual  activities,  pain/discomfort  and anxiety/depression,  will 
be used as a measure of patient perceived global health status 30 days after randomization.  
7.b Ascertainment  
Relevant data will be collected from the medical record during the index hospitalization.  During the 
first 3 days  following  randomization  (or hospital  discharge  if sooner)  active surveillance  is performed 
to ensure all occurrences of myocardial reinfarction are detected. It is required that the site obtains 
troponin  levels  (every  12 hours  for 1 day, and  then daily for the next 2  days)  and electrocardiograms 
(daily for the first 3 days).  These results, in combination with any additional cardiac biomarkers for 
necrosis and electrocardiograms and medical findings, will be reviewed by the Clinical Events 
Committee for each randomized patient, irrespective of a site identified event.  We will therefore be 
able to identify  myocardial  reinfarction  events  that were  not clinically  recognized,  in addition  to those 
had been.  
Study staff will contact the patient at 30 days to ascertain vital status, administer the quality of life 
questionnaire, and determine if there has been a subsequent hospital admission.  Study staff will 
obtain and review the medical records for each readmission and record all relevant data and identify 
the study outcomes. If there is a suspect cardiac  event the staff will submit de -identified copies of the 
documentation  (from  either  the index  admission  or the readmission)  for the Clinical  Events Committee  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 41  
 
F Statistical  Plan  
adjudication.  Study  staff will perform  a final follow -up contact  at 6 months  following randomization  to 
ascertain the patient’s vital status.  
 
 
 
E8 Baseline  and Intervention  Clinical  Characteristics  
Baseline demographic (e.g., age, gender, race), co -morbidity (e.g. cardiovascular risk factors), 
characteristics of cardiac disease (e.g., left ventricular function, number of coronary vessels 
obstructed),  renal  disease,  and medications  (e.g.,  aspirin,  P2Y12  receptor  inhibitor,  anticoagulant, 
beta-blocker statins) will be collected to reflect patient status at the time of randomization.  
Characteristics  describing  the study  intervention including  red blood  cell transfusion  information  (e.g. 
expiration date, leukoreduction, storage solution, ABO) will be recorded. In hospital, hemoglobin 
levels and the number and timing of transfusions will be recorded for the two assigned transfusion 
strategies.  
 
 
 
F1 Sample  Size Determination  and Power  
In the MINT pilot trial, the composite 30 -day rate of death and myocardial infarction was 16.4%.  
Higher  rates  were  observed  in the Kaiser  System  preliminary  data.  Thirty -day rates  of 16.4%,  18%, or 
20% are reasonable for this trial since the proposed study population will not exclude the sickest 
patients as was done in the MINT pilot study.  Using a two -sided inequality test and a simple chi - 
square statistic with alpha=0.05, we determined the samples sizes required to provide 80% and 90% 
power to detect varying relative reductions in the 30 -day event rates for death and myocardial 
infarction between the two assigned treatment groups. Based on these estimates, we plan to enroll a 
sample of 3500 patients. If the rate of missing outcome data is no more than 5%, the trial would have 
3324 patients with analyzable outcome data at 30 -days. Assuming an  overall event rate of 16.4%, the 
trial will have  80% power  to detect a  20% relative  reduction  (i.e. 18.2%  vs. 14.6%)  and >90%  power  to 
detect a 25% relative reduction. If the overall event rate  is 18%, then  the trial will have >80% power to 
detect a 20% relative reduction (i.e. 20% vs. 16%), and if the overall event rate is 20%, the trial will 
have close to 90% power to detect 20% relative reduction (i.e. 22.2% vs.  17.8%).  We also performed  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 42  
  
a simulation  study  to compute  the power  for a log binomial  model  with a  random  intercept  for site and 
a final alpha -level=0.045 to account for the interim monitoring.  We simulated 1000 trials where each 
trial had 60 strata representing the sites, 56 participants within each stratum (i.e. N=3360 patients in 
total), and a mean intra -class correlation (ICC) of 0.05 to 0.08.  The simulations indicate that the 
power is comparable  for the proposed  log binomial  model and  the simple  chi-square  statistic used  for 
the original sample size calculations.  Based on the simulations, the trial will have 81% power to 
detect a 20% relative reduction from 18.2% to 14.6%, and 90% power to detect a 25% relative 
reduction from 18.2% to 14.0%. In addition, the trial will have 85% power to detect a 20% relative 
reduction  from 20% to 16%,  and 89% power  to detect  a 20% relative  reduction  from 22.2%  to 17.8%.  
This pragmatic randomized clinical trial has excellent power to detect clinically meaningful differences 
between the two transfusion strategies with respect to the critical 30 -day composite outcome of death 
and myocardial infarction on both the absolute and the relative scales.  After half of the patients have 
been  enrolled  and followed, we  will monitor  the overall  event rate  in the trial to ensure  that the trial has 
adequate power to detect clinically relevant treatment effects.  
F2 Interim  Monitoring  and Early  Stopping  
The DSMB will review interim analyses of the outcomes by assigned treatment group annually.  The 
interim monitoring is designed to test for evidence of beneficial effect with either treatment strategy 
while maintaining the overall type I error at the pre -specified level.  Stopping rules are based on the 
information (i.e. number of primary outcome events) that has accumulated by each inspection time 
and the shape of the predetermined alpha -spending function.  We recommend that the Lan -DeMets 
approach be used to allocate the type 1 error (i.e. alpha -level) at each interim time point and use of 
O’Brien  Fleming monitoring  boundaries.  The DSMB  may advise  early  termination  of the trial for safety 
reasons or make other recommendations regarding modifications to the protocol.  
The MINT trial will have 4 years of recruitment with a  goal of enrolling N=3500 patients by  June 2021. 
With this timeline, we propose that formal statistical interim monitoring will occur in August or 
September  of 2018, 2019, and  2020  based  on N=298  patients  enrolled  through June  1, 2018,  N=872 
patients enrolled through June 1, 2019, and N=1905 patients enrolled through June 1, 2020, 
respectively.  All calculations assume an overall trial alpha of 0.05.  
With an alpha -spending method, the alpha level to be used at any given look is based upon the 
amount  of information  available  at the monitoring  time.  Once  alpha  is calculated,  boundaries  for the 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 43  
  
standardized  Z-test statistic  are constructed.  A standardized  Z-test statistic  is calculated  based  on the 
estimated relative risk from the log -binomial model which includes assigned transfusion strategy 
(according to the intention to treat principle) as the independent variable.  If the observed Z -test 
statistic crosses the boundary the difference is considered statistically significant at that monitoring 
time.  The “α spending function approach” allows the number and  frequency of monitoring times to  be 
changed at any point during the trial.  
Based  on the anticipated  accrual  shown  in Appendix  4, below  is the table  of the  expected  percent  of 
information, estimated number of participants, the Z -test statistic boundary level and the 
corresponding alpha spent based on the O’Brien -Fleming boundaries.  
Estimated  Boundary  Values  at Each  Interim  Monitoring  Time  Point  
 
  O’Brien  Fleming  
Stage  Information  Level  Boundary  Values  
 Proportion  Number 
Recruited  Bound  Alpha 
Spent  
1 0.0900  298 . . 
2 0.2500  872 ±4.33  <0.001  
3 0.5400  1905  ±2.84  0.005  
4 1.0000  3500  ±1.97  0.045  
 
 
The O’Brien and Fleming (1979) repeated significance tests combined with the Lan and DeMets 
(1983) flexible alpha -spending curves are proposed due to their common usage and their 
conservative  nature  when  the amount of accumulated  data in the trial is small.  They  are designed  to 
stop earlier in the trial if there is overwhelming evidence that there is a difference between the two 
treatment groups.  The ability to detect a difference between the groups becomes easier as the 
amount of information in the trial increases.  
The form of the O’Brien -Fleming  alpha  –spending  function  is: 
𝜶(𝒌) = 𝟐 − 𝟐𝝓 (𝒁𝜶⁄𝟐) 
√𝒊𝒌 
where:  α(k) = cumulative  alpha  at inspection  k 
k = inspection number  
ϕ(x) = the cumulative  distribution  function  of the standard  normal  curve  evaluated  at x. 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 44  
 
 
Zα = the value  of the  standard  normal  curve  where  α is the area in the tail 
ik = the amount of information accumulated in the trial at inspection k  
 
 
We assume  a symmetric  2-sided  boundary, with  each  side spending  α=0.025.  Below  are plots  of the 
cumulative  O’Brien -Fleming alpha -spending  curve  and the corresponding  boundary  plot. We assume 
a symmetric 2 -sided boundary, with each side spending α=0.025.  
 
 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 45  
  
 
 
 
 
 
 
It is possible that the test statistic will cross the monitoring boundary.  Statistical interim monitoring 
results should be taken as one component to the decision as to whether or not to stop a trial.  To stop 
the trial for efficacy, results should be definitive enough to be able to change clinical practice. The 
DSMB  will use the monitoring  information  to determine  its recommendation  to NHLBI.  The DSMB  can 
recommend that the MINT trial should continue as proposed, that the MINT protocol should be 
modified based on the results seen in one treatment comparison or in some well -defined subgroup of 
patients, or  that the  MINT trial should be  terminated early. The  final decision to  stop trial rests  with the 
NHLBI.  If recommendation is to stop the trial, the MINT trial principal investigators shall be consulted 
before a final decision is made.  
In order to ensure that the MINT trial has adequate power, an interim analysis to assess sample size 
will be conducted after when half of the participants are projected to have completed the 30 -day 
follow -up. Revised sample size estimates will be calculated based on the original power and effect 
size estimates  from the trial hypothesis  (80%  power  to detect  a RR=0.80)  and on the observed  overall 
event rate (i.e. the two transfusion groups combined).  The DSMB will evaluate whether the trial 
sample size needs to be increased in order to restore power to maintain the ability to detect a  
clinically meaningful effect size.  

MINT  Trial Protocol  October  24, 2017  
Version  7.1 46  
  
 
 
Since  the MINT  trial compares  two established  transfusion  strategies  with different resource  and cost 
implications, a null result from a well -powered trial would be important for establishing treatment 
guidelines and policy.  Thus, no interim futility analyses will be conducted in the MINT trial.  
F3 Analysis  Plan 
A Screening Log will be developed to include the number of patients with acute myocardial infarction 
and hemoglobin level < 10 g/dL, eligibility and enrollment status. Proportions of eligible and enrolled 
patients will be presented, and reasons why patients are not eligible or enrolled in the trial will be 
tabulated.  Enrollment patterns will be compared across clinical sites and patient groups defined by 
sex and race/ethnicity.  The baseline characteristics and co -interventions of the patients who are 
randomized in the MINT trial will be described, and characteristics of patients in the two assigned 
treatment groups will be compared.  The proportion of enrolled patients who adhere to the assigned 
intervention will be ascertained by evaluating the hemoglobin levels and the number of units of blood 
transfused  during  the index  hospitalization. The  intention -to-treat principle  will be used  to compare  the 
primary outcome (the composite of all -cause mortality and myocardial infarction by 30 days from 
randomization) and each pre -specified secondary outcome by the randomized transfusion strategy 
groups.  A select number of subgroup  analyses will be performed based  on baseline  factors identified 
prior to the initiation of the trial.  
F4 Statistical  Methods  
 
4.a Baseline  Characteristics  of the Enrolled  Patient  Sample  
Descriptive statistics will be examined for all relevant baseline measures collected on the MINT 
randomized patients. Transformations of measures will be considered on the basis of distribution 
diagnostics and outlier analysis.  The baseline characteristics and co -interventions of the patients in 
the overall  study  will be described  using  frequencies,  proportions,  means  and standard  deviations,  or 
medians and first and third quartiles.  Characteristics of patients in the two arms of the trial will be 
compared using chi -square statistics for categorical variables and t -tests or Wilcoxon rank -sum 
statistics for continuous variables.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 47  
  
4.b Adherence  to Assigned  Intervention  
The mean hemoglobin concentration at 1, 2, and 3 days post -randomization will be compared 
between the assigned treatment groups with a Student’s t -test. Mixed random effect models will be 
used  to describe  the daily mean  hemoglobin  concentrations  during  the initial  hospitalization  following 
randomization and to compare these repeated measures by assigned treatment group.  The mean 
number of red blood cell transfusions in each randomized treatment group will be described, and a 
simple Poisson test will be used to test whether the number of units of blood differs significantly by 
assigned transfusion strategy.  
4.c Primary  Outcome  Analysis  
The intention -to-treat principle will be used for all randomized transfusion strategy comparisons of 
study outcomes.  A two -sided test will be used with an alpha -level=0.05 for the primary outcome, the 
composite of all -cause mortality and myocardial infarction (death/MI) by 30 days from randomization. 
The 30 -day event rate for the primary outcome will be compared by assigned transfusion strategy 
using an unadjusted log -binomial regression model with a fixed effect variable for assigned treatment 
strategy and a random effect for clinical site.  The primary analysis will involve the estimated relative 
risk and significance level obtained from the model accounting for interim monitoring and missing 
data.  Event  rates,  the relative  risk and  the absolute  difference  will be from  the observed  data will also 
be presented, and 95% confidence intervals will be calculated.  
If significant imbalances in baseline risk factors are detected between the two randomized treatment 
groups (p<0.05), multivariable log -binomial  regression will be used to adjust for potential confounding 
factors as a sensitivity analysis.  If adherence to the protocol is lower than expected, a per protocol 
analysis, including only  patients  who undergo  transfusion  according  to their assignment and  adjusting 
for baseline  factors  that are associated  with adherence  to the treatment  protocol, will  be conducted  as 
a sensitivity analysis.  
4.d Analysis  of Secondary  and Tertiary  Outcomes  
Event rates,  the relative  risk and the absolute  difference  between  transfusions  strategy  groups  for the 
dichotomous secondary and tertiary outcomes will be calculated with their 95% confidence intervals 
using log -binomial regression methods accounting for clinical site with random effects.  The length of 
hospital  stay from randomization  and from admission  will be analyzed  using  non-parametric  Wilcoxon  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 48  
  
rank sum tests, and long -term mortality will be analyzed with Kaplan -Meier methods and the log rank 
statistic.  The Kaplan -Meier  estimated  mortality  rate in each  treatment  group at  180 days,  the absolute 
difference between the assigned treatment groups at 180 days, and the 95% confidence interval for 
the difference will be presented.  Transfusion strategy comparisons of the EQ -5D quality life  
measures at 30 days will be based on t -tests or the Wilcoxon rank sum test.  No adjustment of the 
alpha level will be made for the secondary and tertiary analyses. Rather the results will be interpreted 
based upon the observed findings, their designation as secondary or tertiary outcomes, and in 
comparison to the primary outcome result.  
The secondary outcomes include: 1) all -cause mortality within 30 days; 2) myocardial reinfarction 
within  30 days;  and 3) the composite  outcome  of all-cause  mortality,  nonfatal  myocardial  reinfarction, 
ischemia driven unscheduled coronary revascularization (percutaneous coronary intervention or 
coronary artery bypass grafting), or readmission to the hospital for ischemic cardiac diagnosis within 
30 days.  
The tertiary outcomes include: 1) all -cause mortality, nonfatal myocardial reinfarction, and unstable 
angina (i.e. acute coronary syndrome) 2) ischemia driven unscheduled coronary revascularization 
within 30 -days; 3) readmission to the hospital for ischemic cardiac diagnosis, 4) congestive heart 
failure within  30 days; 5)  unscheduled  readmission  to hospital  for any  reason  within  30 days; 6)  each 
of the individual  cardiovascular  outcomes  of stroke, pulmonary  embolism  or deep  venous  thrombosis, 
and bleeding within 30 days; 7) each of the individual infectious outcomes of pneumonia, blood 
stream, and urinary tract within 30 days; 8) each of the individual in -hospital outcomes of length of 
hospital  stay post randomization  and number of  days in  intensive  care unit; 9) patient  reported  quality 
of life measures based on the EuroQol  questionnaire (EQ -5D) at 30 days; and 10) all -cause mortality 
at 6-months.  
4.e Missing  Outcome  Data  
For the analysis  of the  primary  outcome,  standard  multiple  imputation  methods  will be used  to impute 
missing 30 -day data.  We expect that missing 30 -day outcome data will be very low in this trial.  All 
patients should have non -missing death and MI data from randomization to hospital  
discharge.  Markov Chain Monte Carlo (MCMC) multiple imputation methods will be used to impute 
the missing  30-day outcome  values  (yes/no)  for death  and MI. Specifically,  a log-binomial  regression 
model to estimate the relationship between the outcome and key covariates (observed baseline and  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 49  
  
in-hospital variables that are clinically relevant and related to the “missingness” of the 30 -day 
outcomes) in the participants with full data. This model will be used to predict the probability of the 
outcome for participants who are missing the 30 day outcomes. Based on these probabilities, ten 
imputed data sets will be created.  A log -binomial model with random effects for site will be estimated 
for each imputed  data set, and the  results  will be  pooled to obtain a  single  estimate of  treatment effect 
with an appropriately adjusted standard error.  As a sensitivity analysis, a log -binomial model with 
random effects for site will be created based on the non -missing 30 -day death/MI data.  Missing data 
will not be  imputed  for the analyses  of the  secondary  and tertiary  hypotheses  unless  critical  issues  are 
noted while investigating the missing 30 -day data.  
4.f Subgroup  Analyses  
Subgroup analyses will be performed based on baseline factors identified prior to the initiation of the 
trial. Clinically relevant subgroup variables include: ST segment elevation MI / non ST segment 
elevation MI,  Universal  Definition  type 1 MI / type 2 MI, type 4b and 4c, baseline  hemoglobin  level (<8, 
8-9, 9-10 g/dL),  revascularization  for treatment  of index  MI, bleeding,  sex, race/ethnicity  (White, Black, 
Other Race and Hispanic, non -Hispanic), age (<70, ≥70 years old), left ventricular dysfunction, 
diabetes status, and creatinine clearance (eGFR <30, 30 -59, ≥60).  The 30 -day event rates by 
assigned transfusion strategy will be compared within each pre -defined subgroup.  The reported 
significance -level will account for the number of treatment comparisons conducted in the study using 
the false discovery rate (FDR) algorithm developed by Benjamini and Hochberg.  In addition, for each 
subgroup variable, a log -binomial regression model including treatment assignment, subgroup  
variable and the interaction between the subgroup variable and treatment assignment will be created, 
and the significance of the interaction term will be used to test whether the randomized treatment 
effect is significantly modified by the designated subgroup variable.  Cox proportional hazards 
regression models will be created with similar covariates in order to test whether the effect of the 
randomized transfusion strategy for 6 -month mortality varies significantly according to the pre - 
specified subgroup variables.  
4.g Combining  Vanguard  and Main  Trial  Data  
In 2016, the Canadian Institutes of Health Research (CIHR) funded a MINT Pilot trial.  This pilot is 
coordinated  by the University  of Montreal, and  the clinical  sites are in Canada.  The DCC  and CCC 
have collaborated with the University of Montreal to ensure that the protocol (eligibility criteria,  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 50  
 
GData  Handling  and Record  Keeping   
interventions, and outcomes) as well as the randomization scheme and the data to be collected are 
nearly identical to those for the main MINT trial.  The CIHR MINT pilot trial was funded to enroll 60 
patients.  This pilot trial will serve as a “Vanguard phase” for the MINT trial and will allow us to 
evaluate the feasibility of the MINT protocol.  After the MINT protocol is approved by the  
DSMB/NHLBI  and the appropriate  ethics  committees  in Canada,  patients  randomized  at the Canadian 
Sites will be enrolled as MINT participants.  All data collection and data coordination for the MINT 
participants  will occur  through  the University  of Pittsburgh  DCC.  Patients  who are randomized  prior to 
the transition date will remain CIHR pilot trial participants throughout their follow -up. The complete 
Vanguard datasets housed at the University of Montreal will be transferred to the University of 
Pittsburgh DCC.  The Vanguard patient data will be merged with the MINT trial data based on  
rigorous comparisons of variable definitions and variable coding.  All Vanguard patients will be 
included in the target sample size and presented in DSMB and published data reports for the MINT 
trial. 
 
 
 
F5 Unblinding  Procedures  
Patients and providers are not blinded in the MINT trial, and thus unblinding procedures are not 
required  for patient  safety.  Trial monitors  and adjudicators  are blinded  to transfusion  strategy,  and the 
DSMB may choose to be blinded to transfusion strategy as they monitor the outcome data.  The 
Medical Monitor and DSMB can request to be unblinded if they deem this necessary.  
 
 
 
G1 Confidentiality  and Security  
Patient identifiers (e.g. name and social security number) will not be sent to the trial DCC, however, 
some  personal  health  information  (e.g. birth date and hospitalization  admission  date)  will be collected 
centrally.  The University of Pittsburgh DCC has a strictly enforced security policy with standard 
operating procedures addressing key security risk areas.  Procedures include password protection, 
limited access to study computers, encryption, IP restriction, basic or digest authentication, and 
firewalls between the Internet and the DCC network and servers.  Regularly scheduled backups and  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 51  
  
archives  are performed  at least  once  daily with  backup  media  copies  of project  files stored  off-site in a 
secure location.  Virus detection will be enforced at the DCC.  All servers will be connected to 
uninterruptible power supplies and housed in a computer room with an alarm.  
Patient  contact  information  will be maintained  exclusively  by the local site and stored  in a secure 
location.  Only local study staff responsible for the 30 day and 6  month telephone calls will have 
access to this contact information.  
G2 Training  
DCC  personnel  at the University  of Pittsburgh  will work with  CCC  personnel  at Rutgers  / Robert  Wood 
Johnson to provide the training necessary for uniform data collection, protocol compliance, and data 
processing.  Major elements to be covered are inclusion and exclusion criteria, procedures and tools 
to monitor adherence to protocol, randomization procedures, event adjudication procedures, adverse 
event reporting, methods for extracting data from different sources, follow -up schedules, what to do 
about missing information, reporting requirements, and use of the Manual of Operations and study 
website.  Instruction will be provided for entering the data, transmitting them to the DCC, interpreting 
edit reports and correcting data.  
On-going  training will  be required  due to the addition  of new  clinical  sites as well as turnover  of staff  at 
the existing clinical sites.  The CCC and DCC will utilize webinars and conference calls to conduct 
detailed distance training sessions.  On-line protocol and data collection training modules will be 
available on the trial website, and focused training sessions will be conducted in conjunction with 
Steering Committee meetings as required.  Throughout the trial, there will be regularly scheduled 
conference calls with the coordinators and data collectors at all sites to discuss issues that arise with 
protocol and data collection.  
G3 Case  Report  Forms  and Source  Documents  
The data collection  forms  for this trial have  been  developed  to facilitate  enrollment and  follow -up while 
still collecting the essential information needed to answer the trial hypotheses. A web -based 
distributed data management system will be used for data entry.  Source documents will be 
maintained at the clinical site.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 52  
 
HStudy  Monitoring,  Auditing,  and Inspecting   
G4 Records  Retention  
Trial patient  records  will be retained  at the clinical  sites and at the Coordinating  Centers  for 6 years 
after MINT data collection is completed.  
G5 Performance  Monitoring  
The DCC will monitor study performance.  Routine reports will be developed to monitor the ongoing 
progress of the study including enrollment and retention. Protocol adherence reports include 
enrollment of ineligible patients, follow -up data collection outside of protocol -defined windows, and 
deviations  from protocol.  The timeliness  of data  collection  and data entry  is routinely  monitored  at the 
DCC using information entered into the data system (evaluation date and data collection date), and 
information stored in the systems inventory files (dates of entry, verification, and submission). The 
DCC will provide reports to the MINT CCC and clinical site coordinators including scheduling and 
delinquency.  Inadequate performance of a site will be reported to the CCC and the site.  The DCC 
and CCC will work with the site to find solutions to challenges.  The DCC and CCC will evaluate the 
performance  at that site to determine  whether  corrections  have  been  made.  Should  problems  persist, 
the Operations Committee will be notified along with recommendations for resolving persisting 
inadequacies.  Trial and site performance reports will be provided to the sites, the CCC, the Steering 
Committee, and the DSMB.  
 
H1 Study  Monitoring  Plan 
The CCC  will coordinate  the study  monitoring  site visits  to each  clinical site.  In addition,  the DCC  will 
conduct data monitoring site visits to clinical sites where specific data issues are identified or data 
concerns  arise based on  a risk-based  monitoring plan.  The risk-based  monitoring plan will be based 
on site performance metrics as well as the results of CCC safety and compliance monitoring visit.  
H2 Auditing  and Inspecting  
During monitoring site visits, CCC personnel will review source documents, including informed 
consent documents, for a random sample of patients and for a defined subset with an exceptional 
number  of inconsistencies  identified  through  the data monitoring  processes  to confirm  that data are 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 53  
 
I Study  Administration   
collected  and entered  accurately.  Problems  adhering  to study  protocols,  data collection,  entry,  and 
management will be identified and corrective procedures will be addressed.  
 
I1 Organization  and Participating  Centers  
 
1.a Clinical  Coordinating  Center  
The Rutgers Robert Wood Johnson School of Medicine, Division of General Internal Medicine is 
responsible  for clinical  coordination  of the trial. The responsibilities  of the Clinical  Coordinating  Center 
are to: 1) Provide administrative and fiscal support for the Clinical Sites; 2) Provide technical, patient 
assessment and Protocol adherence advice to Clinical Site staff; 3) Assist Clinical Sites to correct 
problems with recruitment, Protocol adherence and data collection; 4) Participate in site visits; 5) 
Provide  advice  about any  aspect of  the trial; and 6) Lead  presentation  and publication  of study  results 
for the scientific and lay press.  
A Canadian subsidiary  clinical  coordinating center  to Rutgers Robert  Wood  Johnson Medical  School 
will be housed at the University of Montreal.  The Canadian Coordinating Center will carry out the 
clinical  coordinating  center  responsibilities  listed  above  for the Canadian  sites and will be supervised 
by Dr. Paul Hebert and Dr. Jeffrey Carson.  The Canadian Coordinating Center will have no data 
coordinating function.  
1.b Data  Coordinating  Center  
The Epidemiology Data Center at the University of Pittsburgh is responsible for the data coordination 
of the trial.  The DCC will provide statistical leadership and resources for data management, quality 
control, and analysis.  The responsibilities of the  DCC include: 1) Maintain study website and provide 
all study  materials,  including  the Manual  of Procedures  (MOP)  and Data  Collection  Forms  ; 2) Provide 
a 24 hour randomization service; 3) Establish and maintain an electronic database to receive study 
data and to verify  for completeness, retrieving any missing data  from the centers; 4) Conduct routine 
data edits; 5) Monitor performance to detect problems with recruitment, protocol adherence and data 
collection; 6) Participate in site visits; 7) Provide advice about any aspect of the trial; 8) Perform 
interim and final analyses.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 54  
  
1.c Clinical  Consortium  
The clinical sites recruiting patients into MINT comprise the Clinical Consortium of participating 
hospitals.  Each  site will be  led by the Clinical  Site Director  and Clinical  Site Coordinator.  The Clinical 
Site Director and Coordinator will work closely together to assure successful performance of the trial.  
The responsibilities  of the  Clinical  Site Director  include:  1) To insure  that all medical  staff involved  with 
the care of myocardial  infarction  patients  are well informed  about  the trial; 2) To insure  that all patients 
with myocardial infarction are routinely considered for the trial; 3) To insure that the transfusion 
strategy is  followed, i.e., blood is  given in the Restrictive  Transfusion Strategy  only for symptoms  from 
anemia or when the lower threshold is reached and blood is given in the Liberal Transfusion Strategy 
when Hgb < 10 g/dL; 4) To communicate with Clinical Coordinating Center staff and Data 
Coordinating Center staff any problems or concerns related to the study; and 5) To assist the Clinical 
Site Coordinator as necessary.  
The responsibilities of the Clinical Site Coordinator include: 1) To identify myocardial infarction 
patients  for the trial; 2)  To obtain  informed  consent  from the patient  or surrogate; 3)  To inform  treating 
staff of the patient’s treatment assignment assigned transfusion strategy; 4) To complete data 
collection forms and process data edit  queries; 5) To perform 30 and 180 day telephone follow -up; 6) 
To obtain and  submit all  relevant source  documents for the  Clinical Event Committee adjudication; 7) 
To participate in telephone calls with the Clinical Coordinating Center; 8) To train assistant site 
coordination and other staff at the Clinical Site.  
I2 Funding  Source  and Conflicts  of Interest  
This trial is supported  by the National  Heart  Lung  and Blood  Institute.  All investigators  will be required 
to declare any potential conflicts of interest.  
I3 Committees  
 
3.a Steering  Committee  
The primary decision making body of the MINT trial will be the Steering Committee and will include 
the Principal Investigators of the CCC and DCC, experts in cardiology, transfusion medicine, 
biostatistics,  and the NHLBI  project  officers.  The Steering  Committee  will have  quarterly  conference  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 55  
  
calls and annual  in-person  meetings.  The group  will focus  on the science  of the  study  and to review 
priorities on a regular basis.  
3.b Operations  Committee  
A smaller committee, the Operations Committee, will be a subset of the Steering Committee that will 
meet approximately twice per month via conference call and will be charged with reviewing 
operational and scientific issues for the trial and formulating recommendations for consideration by  
the full Steering  Committee.  The Operations  Committee  will be chaired  by Dr. Carson  and will include 
DCC PI, selected Steering Committee members, and the CCC and DCC project directors.  
The Operations Committee will be empowered to execute operational decisions, and the Operations 
Committee Chair will have the authority to set meeting agendas and appoint committee chairs as 
needed.  The committee  will ensure that  recruitment  for the network is  progressing as  planned  for the 
clinical trial.  In addition to reviewing monthly recruitment reports and quarterly follow -up data 
collection  reports,  the group  will make  specific  recommendations  for strategies  to improve  recruitment 
and protocol implementation.  
3.c Executive  Committee  
A small Executive Committee will identify  high level study  design  and implementation issues  that are 
to be discussed  by the Steering Committee  and to resolve  issues  that require  immediate  action.  The 
committee will include the PIs of the CCC and the DCC and the lead clinical investigator from the 
United States and from Canada.  
3.d Clinical  Events  Committee  
A Clinical  Events  Committee  will be responsible  for adjudication  of myocardial  infarctions.  Committee 
members will be masked to transfusion strategy assignment when they review  and adjudicate patient 
event packets.  
I4 Subject  Stipends  or Payments  
Study  patients  will not receive  any stipends  or payments  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 56  
  
I5 Study  Timetable  
This study  will require  5 years  for completion.  The timeline  and benchmarks  are as follows:  
 
Benchmarks  Timeline  
Planning and Organization Phase 1 : Finalize the Manual of Operations and 
data collection instruments.  Communicate with the Clinical Site Directors at 
each  study  site. Obtain  IRB approval  at clinical  sites with assistance  from CCC 
staff.  Develop computer software for randomization and data entry.  Months  1-4 
 
(9/1/16 – 
12/31/16)  
Planning and Organization Phase 2 : Communicate final study protocol and 
procedures.  Plan and schedule  training.  Hold annual  Collaborators’  Meeting 
for Clinical Site Directors and Coordinators.  Distribute final forms.  Months  5-6 
 
(1/1/17  – 
2/28/17)  
Recruitment and Follow -up Phase : Initiate patient enrollment at the clinical 
sites.  Recruitment  will start once  a site has IRB approval,  an executed  contract, 
and staff have been trained.  Continue for 4.0 years, until patient recruitment is 
completed, or the study is stopped early. Hold annual Collaborators' Meetings.  Month  7- Year 
4. 5. 
 
(3/1/17 – 
2/28/21)  
Close -out and Analysis  Phase : Complete  follow -up and data cleaning.  Perform 
data analysis.  Discuss results at Collaborators’ Meeting.  Present trial results.  Year  4. 5 
 
(3/1/21  – 
8/31/21)  
 
 
The planned  accrual  timeline,  including  the target  and the cumulative  target  enrollment  for each 
quarter, is provided in Appendix 4.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 57  
  
 
The Publications Committee will include physicians, scientists, and statisticians involved with the 
MINT trial.  The chair of the committee will rotate bi -annually.  This committee will be charged with 
coordinating the publication of study results and ensuring that these publications move forward 
according  to schedule.  Our plan is that the primary  results  of the  trial will be  submitted  for publication 
within 9 months of the completion the trial.  This will allow three months for data management and 
cleaning, three months for analysis and three months for manuscript preparation.  
Dr. Carson  will coordinate  the effort  for the primary  results  paper and  the author  byline  will include  the 
writing team “and  the MINT Trial Investigators”.  The primary  results  writing team will be comprised of 
the members of the Steering Committee.  An appendix listing all of the MINT investigators including 
the Steering Committee members, the Site Investigators, the NIH program officers, the DSMB and 
other relevant contributors to the trial will appear at the end of the paper.  
There  will be additional  papers  that evaluate  secondary  hypotheses.  The Publications  Committee  will 
review  proposals  for all non-primary  papers.  Approval  of a paper  proposal  will require  that the topic  is 
clinically relevant, the paper does not overlap with an existing topic, and the general methodology is 
sound.  Secondary papers will have individually named authors and will include “for the MINT Trial 
Investigators” in the author byline.  The investigators who propose the concept will automatically be 
part of the writing team.  Investigators from the Steering Committee and the Sites will have the 
opportunity to sign up for proposed writing teams. If more than 12 investigators sign up for an 
individual writing group, the Publications Committee will allocate investigators to writing teams based 
on contributions to the trial and expertise on the specific topic.  
In order  to ensure  that the trial is using its  resources  to report  the topics  of greatest clinical  relevance, 
the trial Investigators will be asked for ideas for papers and the Steering Committee will be asked to 
identify the ten most important papers.  If a paper on this list is not moving forward according to 
schedule, the Publication Committee will notify the Steering Committee and may recommend a 
change in leadership for the paper.  The Steering Committee will make final decisions about the 
leadership for papers.  
J Publication  Plan 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 58  
  
 
1. Sullivan  MT, Cotten  R, Read  EJ, Wallace  EL. Blood  collection  and transfusion  in the United 
States in 2001. Transfusion (Paris). 2007;47(3):385 -94. PubMed PMID: 17319817.  
 
2. Organization.  WH. 10 facts  on blood  transfusion:  World  Health  Organization;  2015  [cited  2015 
September 11, 2015]. Available from: http://www.who.int/features/factfiles/blood_transfusion/en/ . 
 
3. Heddle  NLY,  ; Barty,  R. Ontario  Data  Collection  Startegy:  Proof  of Concept.  Submitted  to 
MOHLTC. Submitted. 2013.  
 
4. Shehata  NF, A,; Lawrence,  N.; Rothwell,  D.M.;  Hebert,  P.; Fergusson  D. Use of administrative 
data to determine the recipients and trends of blood transfusion. Submitted. 2013.  
 
5. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity -based 
costs  of blood  transfusions  in surgical  patients  at four hospitals.  Transfusion  (Paris).  2010;50(4):753 - 
65. Epub  2009/12/17.  doi: TRF2518  [pii] 
10.1111/j.1537 -2995.2009.02518.x.  PubMed  PMID:  20003061.  
 
6. Zou S, Stramer  SL, Notari  EP, Kuhns  MC, Krysztof D,  Musavi  F, Fang  CT, Dodd  RY. Current 
incidence and residual risk of hepatitis B infection among blood donors in the United States. 
Transfusion  (Paris).  2009;49(8):1609 -20. Epub  2009/05/06. doi:  10.1111/j.1537 -2995.2009.02195.x. 
PubMed PMID: 19413732.  
 
7. Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. 
Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus 
infections among United States blood donors since the introduction of nucleic acid testing. 
Transfusion  (Paris).  2010;50(7):1495 -504. Epub  2010/03/30.  doi: 10.1111/j.1537 -2995.2010.02622.x. 
PubMed PMID: 20345570.  
 
8. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, 
Kissela  B, Kittner  S, Lloyd -Jones  D, McDermott  M, Meigs J, Moy  C, Nichol  G, O'Donnell  CJ, Roger  V, 
Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel -Smoller S, Hong Y. Heart disease and 
stroke  statistics --2007  update:  a report  from the American  Heart  Association  Statistics  Committee  and 
Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69 -171. Epub 2006/12/30. doi: 
CIRCULATIONAHA.106.179918 [pii]  
10.1161/CIRCULATIONAHA.106.179918.  PubMed  PMID:  17194875.  
 
9. Alexander  KP, Chen  AY, Wang  TY, Rao SV, Newby  LK, LaPointe  NM, Ohman  EM, Roe MT, 
Boden WE, Harrington RA, Peterson ED. Transfusion practice and outcomes in non -ST-segment 
elevation acute coronary syndromes. Am Heart J. 2008;155(6):1047 -53. Epub 2008/06/03. doi: 
S0002 -8703(08)00055 -0 [pii]  
KReferences  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 59  
  
10.1016/j.ahj.2008.01.009.  PubMed  PMID:  18513518.  
 
10. Salisbury  AC, Amin  AP, Reid KJ, Wang  TY, Masoudi FA,  Chan  PS, Alexander  KP, Bach  RG, 
Spertus JA, Kosiborod M. Hospital -acquired anemia and in -hospital mortality in patients with acute 
myocardial infarction. Am Heart J. 2011;162(2):300 -9 e3. Epub 2011/08/13. doi: 
10.1016/j.ahj.2011.05.021. PubMed PMID: 21835291.  
 
11. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, 
Schweitzer I,  Yetisir  E. A multicenter,  randomized, controlled clinical  trial of transfusion  requirements 
in critical  care.  Transfusion  Requirements  in Critical  Care  Investigators,  Canadian  Critical  Care  Trials 
Group [see comments]. N Engl J Med. 1999;340(6):409 -17. PubMed PMID: 219.  
 
12. Hajjar  LA, Vincent  JL, Galas  FR, Nakamura  RE, Silva  CM, Santos  MH, Fukushima  J, Kalil 
Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Leao WC, Almeida JP, 
Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NA, Auler JO, Jr. Transfusion requirements after 
cardiac surgery: the TRACS randomized controlled trial. JAMA. 2010;304(14):1559 -67. Epub 
2010/10/14. doi: 304/14/1559 [pii]  
10.1001/jama.2010.1446.  PubMed  PMID:  20940381.  
 
13. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert 
K, Beaupre L, Hildebrand K, Macaulay  W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, 
Horney RA, Magaziner J. Liberal or restrictive transfusion in high -risk patients after hip surgery. N 
Engl J Med.  2011;365(26):2453 -62. Epub  2011/12/16.  doi: 10.1056/NEJMoa1012452.  PubMed  PMID: 
22168590; PMCID: 3268062.  
 
14. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez -Gea V, Aracil C, Graupera I, 
Poca  M, Alvarez -Urturi  C, Gordillo  J, Guarner -Argente  C, Santalo  M, Muniz  E, Guarner  C. Transfusion 
strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368(1):11 -21. doi: 
10.1056/NEJMoa1211801. PubMed PMID: 23281973.  
 
15. Carson  JL, Grossman  BJ, Kleinman  S, Tinmouth  AT, Marques  MB, Fung  MK, Holcomb  JB, 
Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton 
McLaughlin LG, Djulbegovic B, Clinical Transfusion Medicine Committee of the A. Red blood cell 
transfusion: a clinical practice guideline from the AABB*. Ann Intern Med. 2012;157(1):49 -58. doi: 
10.7326/0003 -4819 -157-1-201206190 -00429. PubMed PMID: 22751760.  
 
16. Carson  JLG,  G.; Heddle,  N.M.;  Grossman,  B.J.; Cohn,  C.S.;  Fung,  M.K.;  Gersheimer,  T.; 
Holcomb,  J.B.; Kaplan,  L.J.; Katz,  L.M.;  Peterson,  N.; Ramsey,  G.; Rao,  S.V.;  Roback,  J.D.; Shander, 
A.; Tobian, A.A.R.;. Clinical practice guidelines from the AABB:  Red bloodcell transfuison thresholds 
and storage.  2016;in press.  
 
17. Anderson HT, Kessinger JM, McFarland WJ, Jr., Laks H, Geha AS. Response of the 
hypertrophied  heart  to acute  anemia  and coronary  stenosis.  Surgery.  1978;84(1):8 -15. PubMed 
PMID: 272.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 60  
  
18. Hagl S, Heimisch  W, Meisner H, Erben R, Baum M, Mendler N. The effect of hemodilution on 
regional  myocardial  function  in the presence  of coronary  stenosis.  Basic  Res Cardiol.  1977;72(4):344 - 
64. PubMed  PMID:  9839.  
 
19. Wilkerson  DK, Rosen  AL, Sehgal  LR, Gould  SA, Sehgal  HL, Moss  GS. Limits  of cardiac 
compensation in anemic baboons. Surgery. 1988;103(6):665 -70. PubMed PMID: 232.  
 
20. Carson JL, Duff A, Poses RM, Berlin JA, Spence  RK, Trout R, Noveck H, Strom BL. Effect of 
anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 
1996;348(9034):1055 -60. Epub  1996/10/19.  doi: S0140673696043309  [pii]. PubMed  PMID:  8874456.  
 
21. Silvain J, Abtan J, Kerneis M, Martin R, Finzi J, Vignalou JB, Barthelemy O, O'Connor SA, 
Luyt CE, Brechot  N, Mercadier  A, Brugier  D, Galier  S, Collet JP, Chastre  J, Montalescot  G. Impact  of 
red blood  cell transfusion  on platelet  aggregation  and inflammatory  response  in anemic  coronary  and 
noncoronary patients: the  TRANSFUSION -2 study  (impact of transfusion  of red blood cell on platelet 
activation and aggregation studied with flow cytometry use and light transmission aggregometry). J 
Am Coll Cardiol. 2014;63(13):1289 -96. doi: 10.1016/j.jacc.2013.11.029. PubMed PMID: 24361322.  
 
22. Rodman  T, Close  HP, Purcell  MK. The oxyhemoglobin  dissociation  curve  in anemia.  Ann 
Intern Med. 1960;52:295 -309. PubMed PMID: 731.  
 
23. Kennedy  AC, Valtis  DJ. The oxygen  dissociation  curve  in anemia  of various  types.  JClinInvest. 
1954;33:1372 -81. PubMed PMID: 735.  
 
24. McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, Gow AJ, 
Pawloski  JR, Watke  P, Singel  DJ, Piantadosi  CA, Stamler  JS. Nitric  oxide  in the human  respiratory 
cycle. Nat Med. 2002;8(7):711 -7. doi: 10.1038/nm718. PubMed PMID: 12042776.  
 
25. LaCelle  PL. Alteration  of deformability  of the erythrocyte  membrane  in stored  blood. 
Transfusion (Paris). 1969;9:238 -45. PubMed PMID: 4555.  
 
26. Simchon  S, Jan KM, Chien  S. Influence  of reduced  red cell deformability  on regional  blood 
flow. Am J Physiol. 1987;253:H898 -H903. PubMed PMID: 356.  
 
27. Marik  PE, Corwin  HL. Efficacy  of red blood  cell transfusion  in the critically  ill: a systematic 
review of the literature. Crit Care Med. 2008;36(9):2667 -74. Epub 2008/08/06. doi: 
10.1097/CCM.0b013e3181844677. PubMed PMID: 18679112.  
 
28. Chatterjee  SW, J; Sharma,A.;Lichstein,  E.; Mukherjee,D.  Blood  Transfusion  is Associated  with 
Increased Mortality in Myocardial Infarction -A Meta -analysis and Diversity -Adjusted Study Sequential 
Analysis. Arch Intern Med. 2012;172.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 61  
  
29. Garfinkle  M, Lawler  PR, Filion  KB, Eisenberg  MJ. Red blood  cell transfusion  and mortality 
among patients hospitalized for acute coronary syndromes: a systematic review. Int J Cardiol. 
2013;164(2):151 -7. doi: 10.1016/j.ijcard.2011.12.118. PubMed PMID: 22305811.  
 
30. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly 
patients  with acute  myocardial  infarction.  N Engl J Med.  2001;345(17):1230 -6. PubMed  PMID:  9513.  
 
31. Carson  JL, Reynolds  RC, Klein  HG. Bad bad blood?  Crit Care  Med.  2008;36(9):2707 -8. Epub 
2008/08/30. doi: 10.1097/CCM.0b013e3181843ee7  
00003246 -200809000 -00047  [pii]. PubMed  PMID:  18728495.  
 
32. Carson  JL, Carless  PA, Hebert  PC. Transfusion  thresholds  and other  strategies  for guiding 
allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042. doi: 
10.1002/14651858.CD002042.pub3. PubMed PMID: 22513904.  
 
33. Carson  JL, Carless  PA, Hebert  PC. Outcomes  using  lower  vs higher  hemoglobin  thresholds 
for red blood cell transfusion. JAMA. 2013;309(1):83 -4. doi: 10.1001/jama.2012.50429. PubMed 
PMID: 23280228.  
 
34. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. 
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. 
Cochrane  Database  Syst Rev. 2016;10:CD002042.  doi: 10.1002/14651858.CD002042.pub4.  PubMed 
PMID: 27731885.  
 
35. Docherty  AB, O'Donnell  R, Brunskill  S, Trivella  M, Doree  C, Holst L,  Parker M, Gregersen  M, 
Pinheiro de Almeida J, Walsh TS, Stanworth SJ. Effect of restrictive versus liberal transfusion 
strategies on outcomes in patients with cardiovascular disease in a non -cardiac surgery setting: 
systematic  review  and meta -analysis.  BMJ.  2016;352:i1351.  doi: 10.1136/bmj.i1351.  PubMed  PMID: 
27026510; PMCID: PMC4817242.  
 
36. Patel NN, Avlonitis VS, Jones HE, Reeves BC, Sterne JA, Murphy GJ. Indications for red 
blood  cell transfusion  in cardiac  surgery:  a systematic  review  and meta -analysis.  Lancet  Haematol. 
2015;2(12):e543 -53. doi: 10.1016/S2352 -3026(15)00198 -2. PubMed PMID: 26686409.  
 
37. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, Panza JA. 
Conservative  versus  liberal  red cell transfusion  in acute  myocardial  infarction  (the CRIT  Randomized 
Pilot Study). Am J Cardiol. 2011;108(8):1108 -11. Epub 2011/07/28. doi: 
10.1016/j.amjcard.2011.06.014. PubMed PMID: 21791325.  
 
38. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Joint 
ESCAAHAWHFTFfUDoMI, Authors/Task Force Members C, Thygesen K, Alpert JS, White HD, 
Biomarker  S, Jaffe  AS, Katus  HA, Apple  FS, Lindahl  B, Morrow  DA, Subcommittee  ECG,  Chaitman 
BR, Clemmensen PM, Johanson P, Hod H, Imaging S, Underwood R, Bax JJ, Bonow JJ, Pinto F, 
Gibbons RJ, Classification S, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Intervention S,  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 62  
  
Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Trials, Registries S, Ohman 
EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Trials, Registries S, Januzzi JL, 
Nieminen MS, Gheorghiade M, Filippatos G, Trials, Registries S, Luepker RV, Fortmann SP, 
Rosamond  WD, Levy D, Wood D, Trials, Registries S, Smith SC, Hu D, Lopez -Sendon JL, Robertson 
RM, Weaver  D, Tendera  M, Bove  AA, Parkhomenko  AN, Vasilieva  EJ, Mendis  S, Guidelines  ESCCfP, 
Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck -Brentano C, Hasdai D, Hoes 
A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes 
PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Document R, Morais J, Aguiar C, Almahmeed 
W, Arnar  DO, Barili  F, Bloch  KD, Bolger  AF, Botker  HE, Bozkurt  B, Bugiardini  R, Cannon  C, de Lemos 
J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske 
BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of 
myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581 -98. doi: 10.1016/j.jacc.2012.08.001.  
PubMed  PMID:  22958960.  
 
39. Roubinian  N. Variation  of Transfusion  Practice.  2015  (personal  communication).  
 
40. Salisbury AC, Reid KJ, Amin AP, Spertus JA, Kosiborod M. Variation in the incidence of 
hospital -acquired anemia during hospitalization with acute myocardial infarction (data from 57 US 
hospitals).  Am J Cardiol.  2014;113(7):1130 -6. doi: 10.1016/j.amjcard.2013.12.017.  PubMed  PMID: 
24485696.  
 
41. Salisbury  AC, Reid KJ, Marso  SP, Amin  AP, Alexander  KP, Wang  TY, Spertus  JA, Kosiborod  
M. Blood  transfusion  during  acute  myocardial  infarction:  association  with mortality  and variability 
across  hospitals.  J Am Coll Cardiol.  2014;64(8):811 -9. doi: 10.1016/j.jacc.2014.05.040.  PubMed 
PMID: 25145526.  
 
42. Sherwood MW,  Wang  Y, Curtis  JP, Peterson  ED, Rao SV. Patterns  and outcomes  of red 
blood cell transfusion in patients undergoing percutaneous coronary intervention. JAMA. 
2014;311(8):836 -43. Epub 2014/02/27. doi: 10.1001/jama.2014.980. PubMed PMID: 24570247.  
 
43. Magruder  JT, Blasco -Colmenares  E, Crawford  T, Alejo  D, Conte  JV, Salenger  R, Fonner  CE, 
Kwon CC, Bobbitt J, Brown JM, Nelson MG, Horvath KA, Whitman GR. Variation in Red Blood Cell 
Transfusion  Practices  During  Cardiac  Operations  Among  Centers  in Maryland:  Results  From  a State 
Quality -Improvement Collaborative. Ann Thorac Surg. 2017;103(1):152 -60. doi: 
10.1016/j.athoracsur.2016.05.109. PubMed PMID: 27553501.  
 
44. Miller  YB, G.; Benjamin,  R.; Eklund,  D.K.;  et al. Practice  Guidelines  for Blood  Transfusion;  A 
Complilation from Recent Peer -Reivewed Literature. American Red Cross. 2nd ed: American Red 
Cross; 2007.  
 
45. Carson  JL, Grossman  BJ, Kleinman  S, Tinmouth  AT, Marques  MB, Fung  MK, Holcomb  JB, 
Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian AA, Weinstein R, Swinton 
McLaughlin  LG, Djulbegovic  B. Red Blood  Cell Transfusion:  A Clinical  Practice  Guideline  From  the 
AABB. Annals of internal medicine. 2012. Epub 2012/03/29. doi: 10.1059/0003 -4819 -156-12- 
201206190 -00429. PubMed PMID: 22454395.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 63  
  
46. Qaseem  A, Humphrey  LL, Fitterman  N, Starkey  M, Shekelle  P, Clinical  Guidelines  Committee 
of the American College of P. Treatment of anemia in patients with heart disease: a clinical practice 
guideline from the American College of Physicians. Ann Intern Med. 2013;159(11):770 -9. Epub 
2013/12/04. doi: 10.7326/0003 -4819 -159-11-201312030 -00009. PubMed PMID: 24297193.  
 
47. American College of Emergency P, Society for Cardiovascular A, Interventions, O'Gara PT, 
Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire 
FM, Franklin BA,  Granger CB, Krumholz  HM, Linderbaum  JA, Morrow  DA, Newby  LK, Ornato  JP, Ou 
N, Radford  MJ, Tamis -Holland  JE, Tommaso  CL, Tracy  CM, Woo YJ, Zhao  DX, Anderson  JL, Jacobs 
AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs 
RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW. 2013 ACCF/AHA guideline for the 
management of ST -elevation myocardial infarction: executive summary: a report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J 
Am Coll Cardiol. 2013;61(4):485 -510. doi: 10.1016/j.jacc.2012.11.018. PubMed PMID: 23256913.  
 
48. O'Gara  PT, Kushner  FG, Ascheim  DD, Casey  DE, Jr., Chung  MK, de Lemos  JA, Ettinger  SM, 
Fang  JC, Fesmire  FM, Franklin  BA, Granger CB,  Krumholz  HM, Linderbaum JA, Morrow  DA, Newby 
LK, Ornato JP, Ou N, Radford MJ, Tamis -Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao DX, 
Force CAT. 2013 ACCF/AHA guideline for the management of ST -elevation myocardial infarction: 
executive summary: a report of the American College of Cardiology Foundation/American Heart 
Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529 -55. doi: 
10.1161/CIR.0b013e3182742c84. PubMed PMID: 23247303.  
 
49. Rogers  GMB,  M.; Cela,  D.; Cleeland,  C. et al. NCCN  Guidelines  Version  2.2014  Cancer - and 
Chemotherapy -Induced  Anemia.  NCCN  Clinical  Practice  Guidelines  in Oncology  (NCCN  Guidelines) 
[Internet]. 2013.  
 
50. Patient  Blood  Management  Guidelines:  National  Blood  Authority,  Australia;  2012  [June  14, 
2014]. Available from: http://www.blood.gov.au/pbm -guidelines  
 
51. Hamm CW,  Bassand  JP, Agewall S, Bax  J, Boersma E, Bueno  H, Caso  P, Dudek D,  Gielen S, 
Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, Guidelines 
ESCCfP, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck - 
Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu  
BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Document R,  Windecker 
S, Achenbach S, Badimon L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, 
Goudevenos  J, Gulba  D, Hambrecht  R, Herrmann  J, Kastrati  A, Kjeldsen  K, Kristensen  SD, Lancellotti 
P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, 
Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute  
coronary syndromes in patients presenting without persistent ST -segment elevation: The Task Force 
for the management of acute coronary syndromes (ACS) in patients presenting without persistent  ST- 
segment  elevation  of the European  Society  of Cardiology  (ESC).  Eur Heart  J. 2011;32(23):2999 -3054. 
doi: 10.1093/eurheartj/ehr236. PubMed PMID: 21873419.  
 
52. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, 
Holcomb  JB, Kaplan  LJ, Katz LM, Peterson  N, Ramsey  G, Rao SV, Roback  JD, Shander  A, Tobian  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 64  
  
AA. Clinical  Practice  Guidelines  From  the AABB:  Red Blood Cell  Transfusion  Thresholds  and 
Storage. JAMA. 2016. doi: 10.1001/jama.2016.9185. PubMed PMID: 27732721.  
 
53. Alexander  J, Cifu AS. Transfusion  of red blood  cells.  JAMA.  2016.  doi: 
10.1001/jama.2016.12870. PubMed PMID: 27732722.  
 
54. Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Chung KW, Henry RA, 
Berger  JJ, Kuehnert  MJ, Basavaraju  SV. Continued  decline  in blood  collection  and transfusion  in the 
United States -2015. Transfusion (Paris). 2017;57 Suppl 2:1588 -98. doi: 10.1111/trf.14165. PubMed 
PMID: 28591469.  
 
55. Roubinian  NH, Escobar  GJ, Liu V, Swain  BE, Gardner  MN, Kipnis  P, Triulzi  DJ, Gottschall  JL, 
Wu Y, Carson JL, Kleinman SH, Murphy EL, Epidemiology NR, Donor Evaluation S. Trends in red 
blood cell transfusion and 30 -day mortality among hospitalized patients. Transfusion (Paris). 
2014;54(10 Pt 2):2678 -86. doi: 10.1111/trf.12825. PubMed PMID: 25135770; PMCID: 4197097.  
 
56. Proceedings  from the National Summit on  Overuse.  September 24, 2012  2012 [August 5, 
2017].  Available  from:  https://www.jointcommission.org/assets/1/6/National_Summit_Overuse.pdf . 
 
57. Rao SV, Chiswell K, Sun JL, Granger CB, Newby LK, Van de  Werf F,  White HD, Armstong 
PW, Califf  RM, Harrington  RA. International  variation  in the use of blood  transfusion  in patients  with 
non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2008;101(1):25 -9. Epub 
2007/12/26. doi: S0002 -9149(07)01822 -X [pii]  
10.1016/j.amjcard.2007.07.042.  PubMed  PMID:  18157960.  
 
58. Spitalnik SL,  Triulzi  D, Devine  DV, Dzik WH, Eder  AF, Gernsheimer  T, Josephson  CD, Kor DJ, 
Luban NL, Roubinian NH, Mondoro T, Welniak LA, Zou S, Glynn S, State of the Science in 
Transfusion  Medicine  Working  G. 2015 proceedings  of the  National Heart, Lung, and  Blood Institute's 
State of the Science in Transfusion Medicine symposium. Transfusion (Paris). 2015. doi: 
10.1111/trf.13250. PubMed PMID: 26260861.  
 
59. Vlaar  AP, Juffermans  NP. Transfusion -related  acute  lung injury:  a clinical  review.  Lancet. 
2013. doi: 10.1016/S0140 -6736(12)62197 -7. PubMed PMID: 23642914.  
 
60. Klein  HG, Spahn  DR, Carson  JL. Red blood  cell transfusion  in clinical  practice.  Lancet. 
2007;370(9585):415 -26. Epub 2007/08/07. doi: S0140 -6736(07)61197 -0 [pii]  
10.1016/S0140 -6736(07)61197 -0. PubMed  PMID:  17679019.  
 
61. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez -Aviles F, Fox KA, 
Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non -ST- 
segment  elevation  acute  coronary  syndromes.  Eur Heart  J. 2007;28(13):1598 -660. Epub  2007/06/16. 
doi: 10.1093/eurheartj/ehm161. PubMed PMID: 17569677.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 65  
  
62. Schulman  S, Kearon  C, Subcommittee  on Control  of Anticoagulation  of the S, Standardization 
Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical 
investigations of antihemostatic medicinal products in non -surgical patients. J Thromb Haemost. 
2005;3(4):692 -4. doi: 10.1111/j.1538 -7836.2005.01204.x. PubMed PMID: 15842354.  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 66  
  
 
 
 
L Appendices  
Version  7.1 67  
 L1 Appendix 1:  Standardized approach  and script to  be used  to 
seek  permission  from  attending  physician  to recruit  a patient  
 
 
For each  patient who  is potentially  eligible  for the trial, the  MINT  site investigator  or coordinator 
will contact  the patient’s  attending  physician,  with expertise  in cardiovascular  care, and  use the 
following script:  
“Dr. <name> I am calling to seek your permission to approach your patient <name> for 
consent to participate in the MINT trial.  This is an NIH -sponsored trial that enrolls 
patients with an acute myocardial infarction and a hemoglobin level <10.  According to 
the protocol, those assigned to the Liberal Arm receive red blood cell transfusions to 
maintain a hemoglobin level ≥ 10.  Those assigned to the Restrictive Arm will be 
permitted  to receive  a transfusion  if the  hemoglobin  concentration  falls below  8 g/dL and 
will be strongly recommended to receive transfusion if the hemoglobin concentration is 
below 7 g/dL and you determine that a transfusion is in the patient’s best  
interest.  Transfusion is always permitted for active bleeding or if there are angina 
symptoms  that you believe  are related  to the anemia  and are not adequately  controlled 
with medications.  Patients can be withdrawn from the transfusion protocol if clinical 
circumstance change and adherence to the protocol places the patient at risk.”  
“We want to confirm that <name> is an appropriate candidate for the trial; and that in 
your clinical  judgement both  approaches  to transfusion  are consistent  with good  medical 
care for this patient.”  
The first paragraph  of the script will  be used  the initial  time the trial team  contacts  the physician 
but could be skipped if the physician is already familiar with the protocol.  The second 
paragraph will be stated when contacting an attending physician for any potential patient 
whether or not the physician has been contacted by the MINT team in the past.  Patients will 
only be approached for consent if their physician confirms his/her belief that either transfusion 
strategy is appropriate, per the second paragraph.  
 
 
 
 
 
Version  7.1 68  
 L2 Appendix  2: MINT  Data  Elements  by Study  Time  Point  
 
  
 
Screening   
 
Baseline   
 
Randomization   
12 hours Post 
Randomization   
 
Day 1  
 
Day 2  
 
Day 3  
Daily  Up to 
30 Days  Hospital  
Discharge/  
30 Days   
30 Day 
Follow -up  
6 Month 
Follow -up 
Confirm  Eligibility  X           
Informed  Consent  X           
Hemoglobin  Levela  
Xb,c   
Xb Xb Xb X    
Troponin  Levela  
Xb,c  
Xb Xb Xb Xb X    
ECGa  
Xb,c   
Xb Xb Xb X    
Demographics  X           
Medical  History   X          
Medications   X          
Implement  Transfusion  Strategy    X -------------------------------- -------------------------------- -------------------------------  X    
RBC Transfusionsd   X -------------------------------- -------------------------------- -------------------------------  X    
Study  Outcomes          X X Xe 
Quality  of Life (EQ-5D)          X  
Vital  Status          X X X 
Assessment  of AEs and UPs 
Safety Monitoring   
X -------------------------------- -------------------------------- -------------------------------- -------------------------------- -----------------  X  
            
            
a in addition  to required  time points,  all performed  for clinical  reasons  are collected         
b required,  if still in hospital            
c within the  24 hours  prior  to randomization            
d including  unit information  (e.g,  leukoreduction)           
d mortality  outcome  only           
 
 
 
 L3 Appendix  3: SAE and UP Event  Reporting  Timelines  
 
What  Event  is Reported  When  is Event  Reported  By Whom  is 
Event  Reported  To Whom  is Event  
Reported  
 
Fatal or life -threatening 
unexpected,  suspected  serious 
adverse reactions   
 
Within  7 calendar  days  of initial 
receipt of information   
Investigator  Local/internal  IRBs 
NHLBI  and/or  Data 
Coordinating  Center  (DCC)  
Sponsor  or 
designee1 FDA (if IND study)  
 
 
Non-fatal, non -life-threatening 
unexpected,  suspected  serious 
adverse reactions   
 
 
Within  15 calendar  days  of initial 
receipt of information   
Investigator  Local/internal 
IRBs/Institutional  Officials 
NHLBI and/or DCC  
 
Sponsor  or 
designee  FDA (IND/Marketed 
Products)  
All participating 
investigators  
 
Unanticipated  adverse  device 
effects   
Within 10 working days of 
investigator  first learning  of effect   
Investigator  Local/internal  IRBs 
NHLBI  and/or  DCC 
Sponsor  or 
designee  FDA (if IDE study)  
Unanticipated  Problem  that is not 
an SAE  Within  14 days  of the investigator 
becoming aware of the problem   
Investigator  Local/internal 
IRBs/Institutional  Officials, 
NHLBI and/or DCC  
 
All Unanticipated  Problems2 Within 30 days of the IRB’s 
receipt  of the report  of the UP 
from the investigator.  IRB OHRP  
Investigator3 External  IRBs 
 
1. Designee  is appointed  by the sponsor;  for example,  DCC, CRO. 
2. Per OHRP  guidance:  only when  a particular  AE or series  of AEs is determined  to meet the criteria  for 
an UP should a report of the AE(s) be submitted to the IRB at each institution under the HHS 
regulations at 45 CFR part 46. Typically, such reports to the IRBs are submitted by investigators.  
3. Investigators  should  also take into account  local IRB guidance  if reporting  timelines  for UPs are 
shorter than OHRP guidance  
 
 
 
 
 
 
 
 
Version  7.1 69 
MINT  Trial Protocol  October  24, 2017  
Version  7.1 70  
  
 
L4 Appendix  4: Accrual  Timeline  Milestones  
 
 
The principles  guiding  the accrual  timeline are  as follows.  The specific  target numbers  are 
provided in the table.  
• Recruitment  will start 6 months  after funding  of the trial 
• 50% of the projected  sites will initiate  recruitment  between  month  6 and 12 
• All sites will be recruiting  by month  18 
• Recruitment  will extend  for 4 years  
• The recruitment  rate will get faster  over time. 
• Total  sample  size is 3500  patients.  
 
 
 
Date Proposed 
Target  Accrual  Proposed 
Cumulative 
Accrual  
6/1/17  Start Start 
9/1/17  43 43 
12/1/17  63 106 
3/1/18  86 192 
6/1/18  106 298 
9/1/18  121 419 
12/1/18  136 555 
3/1/19  151 706 
6/1/19  166 872 
9/1/19  191 1063  
12/1/19  227 1290  
3/1/20  275 1565  
6/1/20  340 1905  
9/1/20  380 2285  
12/1/20  400 2685  
3/1/21  405 3090  
6/1/21  410 3500  
MINT  Trial Protocol  October  24, 2017  
Version  7.1 71  
 
 
 
 
 
 
 
 
 
 
